Engineered nanovesicles as checkpoint blockers for cancer immunotherapy

Replacement therapies against the PD-1/PD-L1 inhibitor axis were developed through engineered nanovesicles or platelets encoding exogenous protein receptors, combining small molecule drugs, addressing the resistance of existing checkpoint antibody therapies Sex and cost issues have achieved effective immunotherapy for a variety of cancers.

CN111787945BActive Publication Date: 2024-11-29NORTH CAROLINA STATE UNIV
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN201980013676.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2019-02-15
Publication Date
2024-11-29
Estimated Expiration
2039-02-15

AI Technical Summary

Technical Problem

In the existing cancer immunotherapy, checkpoint antibody therapy is highly resistant to multiple cancers, costly, and most of them are from mice, which are difficult to widely use. It is necessary to develop alternative anti-PD-1/PD-L1 inhibition. Method of agent shaft.

Method used

Using engineered nanovesicles or engineered platelets encoding exogenous protein receptors, including PD-1, TIGIT, LAG3 or TIM3, combined with small molecule drugs such as 1-MT or antibodies, such as nivolumab, encapsulated in nanometers Vesicles or platelets, used in cancer immunotherapy.

Benefits of technology

Effectively restore CD8+ T cells viability, enhance the effect of immunotherapy, show positive response to a variety of cancers, reduce drug resistance, reduce treatment costs, and improve treatment popularity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111787945B_ABST
    Figure CN111787945B_ABST
Patent Text Reader

Abstract

The present invention discloses engineered nanovesicles and engineered platelets comprising exogenous proteins and methods for treating cancer, the methods comprising administering the engineered nanovesicles and engineered platelets to a subject.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention was made with the support of a government grant of 1L1TR001111 granted by the National Institutes of Health. The government holds certain rights to this invention. This application claims the benefit of U.S. Provisional Application No. 62 / 630,956, filed February 15, 2018, the entire contents of which are incorporated herein by reference. Background Technology

[0002] Surgical intervention is the primary clinical treatment option for most solid tumors. However, due to incomplete tumor resection, surgery often carries the risk of recurrence. Furthermore, studies have shown that surgery can sometimes promote cancer metastasis. Therefore, developing effective strategies to treat cancer or prevent postoperative recurrence is of great interest. Cancer immunotherapy aims to utilize the body's immune system to eliminate cancer cells. Encouragingly, tumor antigen-specific T cells hold promise for clearing residual tumor cells. CD8 + T cells are one of the most important lymphocyte responses in tumors, especially lymphocytes carrying mutated genes. In fact, these neoantigens (mutated protein-derived antigens) are specific to CD8. + T cells can infiltrate tumors and produce positive immunotherapy outcomes. However, expression of programmed death-ligand 1 (PD-L1) in tumors suppresses T cell responses, leading to T cell depletion. ex PD-L1 ligands inhibit T cells via the inhibitory receptor programmed death-1 (PD-1). ex Cells. In addition, T ex Cells can inhibit the production of immune cytokines such as IFN-γ, TNF-α, granzyme B, and perforin, leading to tumor necrosis. Blocking the PD-1 / PD-L1 axis with checkpoint antibodies can enhance T cells' ability to eradicate tumors. ex Cells have regained vitality in clinical treatment and have shown positive responses to various human cancers, particularly melanoma. In melanoma patients, the success rate of checkpoint antibody therapy is approximately 37% to 38%, while similar response rates have been observed in other types of cancer, such as renal cell carcinoma, non-small cell lung cancer, and bladder cancer. However, anti-PD-1 therapy is not effective against all types of cancer. In fact, more than half of patients develop resistance to PD-1 antibody therapy, and only a small percentage benefit from multiple immunosuppressants. Furthermore, most existing humanized antibodies are derived from mice, requiring complex design and isolation. Therefore, the cost of checkpoint antibody therapy remains prohibitive for many patients. Thus, there is a need to develop alternative approaches to the anti-PD-1 / PD-L1 inhibitor axis. Summary of the Invention

[0003] This invention discloses methods and compositions relating to engineered nanovesicles or engineered platelets encoding one or more exogenous protein receptors, the compositions of which can be used as checkpoint blockers in cancer immunotherapy.

[0004] In one aspect, the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3.

[0005] This article also discloses engineered nanovesicles or engineered platelets of any of the foregoing aspects, wherein the engineered nanovesicles or engineered platelets are derived from dendritic cells, stem cells, immune cells, megakaryocyte progenitor cells, or macrophages.

[0006] In one aspect, this document discloses pharmaceutical compositions comprising engineered nanovesicles or engineered platelets, including any of the foregoing aspects.

[0007] This document also discloses pharmaceutical compositions of any of the foregoing aspects, which further include therapeutic agents such as, for example, small molecules (including but not limited to 1-methyl-tryptophan (1-MT), norharmane, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vincristine, cyclophosphamide, and 5-fluorouracil), siRNA, peptides, peptide mimics, or antibodies (such as, for example, and anti-PDL-1 antibodies, including but not limited to atezolizumab, durvalumab, and avelumab).

[0008] In one aspect, this document discloses pharmaceutical compositions of any of the foregoing aspects, wherein the therapeutic agent is encapsulated in the engineered nanovesicles or engineered platelets.

[0009] This article also discloses methods for treating cancers (including but not limited to melanoma, renal cell carcinoma, non-small cell lung cancer, and / or bladder cancer) in subjects, comprising administering the engineered nanovesicles, engineered platelets, or any of the foregoing pharmaceutical compositions to a cancer patient.

[0010] In one aspect, this document discloses a method for treating a subject with cancer in any of the foregoing aspects, wherein the engineered nanovesicles, engineered platelets, or pharmaceutical composition are administered at least every 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, 32 hours, 34 hours, 36 hours, 38 hours, 40 hours, 42 hours, 44 hours, 46 hours, or 48 hours, every 3 days, or every 4 days. The medication is administered to the patient once every 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days, or once every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.

[0011] This article also discloses methods for treating cancer in subjects in any of the foregoing aspects, wherein the engineered nanocapsules, engineered platelets, or pharmaceutical compositions are administered at least once, twice, three times, four times, five times, six times, or seven times per week.

[0012] In one aspect, this document discloses a method for treating a subject with cancer in any of the foregoing aspects, wherein the dose of the engineered nanovesicles, engineered platelets, or pharmaceutical composition administered is from about 10 mg / kg to about 100 mg / kg.

[0013] This article also discloses methods for treating cancer in subjects in any of the foregoing aspects, which further include the administration of chemotherapy agents.

[0014] This article discloses methods for treating cancer in subjects in any of the foregoing aspects, wherein the engineered nanovesicles, engineered platelets, or pharmaceutical compositions are administered after surgical removal of the tumor. Attached Figure Description

[0015] The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments, and together with the specification, illustrate the disclosed compositions and methods.

[0016] Figures 1A, 1B, 1C, 1D, 1E, 1F, 1G, 1H, and 1I show schematic diagrams and characteristics of PD-1 blockade NVs for cancer immunotherapy. Figure 1A shows a schematic diagram of the preparation of PD-1 NVs loaded with 1-MT. (i) Construction of a stable HEK 293T cell line expressing the mouse PD-1 receptor. (ii) Harvesting of cell membranes expressing the PD-1 receptor. (iii) Preparation of PD-1 NVs by extrusion. Figure 1B shows PD-L1 expelling CD8 through interaction with the PD-1 receptor. +T cells. IDO expression is induced by Treg cells, which inhibits CD8. + Cell viability. Figure 1C shows depleted CD8 cells induced by PD-L1 blockade with PD-1 NV. + Cells recover to attack tumor cells. The release of the IDO inhibitor 1-MT also depletes depleted CD8 cells. + Cell recovery. Figure 1D shows the establishment of a HEK 293T cell line stably expressing mouse PD-1 on the cell membrane. The cell membrane was labeled with WGA Alexa-Fluor 488 dye. Scale bar: 10 μm. Figure 1E shows a TEM image illustrating the shape and size of the PD-1 NV. Scale bar: 100 nm. Figure 1F shows a cryo-scanning electron microscopy (SEM) image illustrating the natural shape of the PD-1 NV (scale bar: 100 nm). Figure 1G shows a confocal image indicating the presence of DsRed-PD-1 NV by red dots. Scale bar: 1 μm. Figure 1H shows the size distribution of the PD-1 NV as measured by DLS. Figure 1I Western blot analysis showed expression of the mouse PD-1 receptor on the NV and whole-cell lysis (HCL) of stable cell lines. Na... + K + ATPase was used as a loading control.

[0017] Figures 2A, 2B, and 2C show the characteristics of PD-1 MV. Figure 2A shows a confocal image indicating the presence of DsRed-PD-1 MV by red dots. Scale bar: 1000 nm. Figure 2B shows the size distribution of PD-1 MV as measured by DLS. Figure 2C Displays the electromotive force of free NV and PD-1 NV (n=3). Error bars, mean ± standard deviation.

[0018] Figures 3A, 3B, 3C, 3D, 3E, 3F, 3G, 3H, and 3I show the in vitro biological behavior and in vivo biodistribution of PD-1 NV. Figure 3A shows DsRed-PD-1 NV bound to the membrane of B16F10 cancer cells. Cy5.5 (50 μg / mL) labeled PD-1 NV (50 μg / mL) or free PD-1 NV was incubated with B16F10 cells for 2 h. The B16F10 cell membrane was detected using WGA Alexa-Fluor 488 dye (scale bar: 10 μm). Figure 3B shows the reception of DsRed-PD-1 NV via DCs. PD-1 NV (50 μg / mL) was incubated with DCs for 2 h, and the DC membrane was detected using WGA Alexa-Fluor 488 dye. Scale bar: 10 μm. Figure 3C shows the co-localization of PD-1 NV and PD-L1 proteins after transfecting B16F10 cells with EGFP-PD-L1 plasmid for 20 h, followed by incubation with PD-1 NV (50 μg / mL) for 5 h (scale bar: 10 μm). The image above is a magnified view of the white ring in the bottom image. Figure 3D shows PD-1 NV in B16F10 cells (gated to DsRed). + (Above) Representative flow cytometry analysis images of the combination. PD-1 NV (50 μg / mL) was incubated with B16F10 cells for 2 h. Or, as shown, the cells were incubated with aPD-L1 antibody (20 μg / mL) for 4 h, and then the PD-1 NV was added to the culture medium. Figure 3E shows the interaction between PD-1 (on NV) and PD-L1 (on B16F10 cells) detected by CO-IP and Western blotting. Figure 3F shows Cy5.5-labeled free NV (200 μL, 5 mg / mL) and PD-1 NV (200 μL, 5 mg / mL) injected via mouse tail vein. Fluorescence was measured at different time points (n=3) as shown. Error bars, mean ± standard deviation. Figure 3G shows IVIS spectral images of the distribution of free NV and PD-1 NV in tumors and major organs. Left: lung, heart, and liver. Right: spleen, kidney, and tumor. Figure 3H shows the fluorescence intensity per gram of tissue in the tumor and major organs as shown (n=3). Error bars, mean ± standard deviation. Figure 3I This image shows the distribution of PD-1 NV in organs and observation of tumor sections using confocal microscopy. Scale bar: 100 μm.

[0019] Figures 4A and 4B show the in vivo antitumor effects of different doses of PD-1 NV administered via tail vein injection. Figure 4A shows in vivo bioluminescence imaging of B16F10 melanoma tumors. Figure 4BThe mean tumor volume of mice treated with different methods is shown (n=7). Error bars, mean ± standard error. NS: No significant difference, *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA using Tukey post-hoc tests.

[0020] Figures 5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H, 5I, and 5J show the in vivo antitumor effect of PD-1 NV. Figure 5A shows in vivo bioluminescence imaging of B16F10 melanoma tumors in different mouse groups at different time points after tail vein injection of free NV, PD-1 NV, and PD-L1 antibody. Day 0: The day of the first treatment. Figure 5B shows the mean tumor volume of mice in different treatment groups (n=7). Error bars, mean ± standard deviation. Figure 5C shows images of representative tumors extracted from euthanized mice in different groups (n=7). Error bars, mean ± standard deviation. Figure 5D shows the survival curves of mice treated with PD-1 NV, PD-L1 antibody, and free NV (n=10). Figure 5E shows the body weight of treated mice and control mice. Error bars, mean ± standard deviation. Figure 5F shows the IFN-γ level in mouse serum isolated on day 20 after the first indicated treatment (n=3). Error bars, mean ± standard deviation. Figures 5G and 5H show T cells (gated to CD3) in therapeutic tumors analyzed by flow cytometry. + Representative curves (5F) and quantitative analysis (5G) (n=3) on cells. Error bars, mean ± standard deviation. Figures 5I and 5J show infiltrating CD4 cells. + T cells and CD8 + Representative images of tumor sections with immunofluorescence staining of T cells (5I) and quantitative analysis (5J) (n=3). Error bars, mean ± standard deviation. Scale bar: 100 μm. Overall, NS: no significant difference, *P<0.05, **P<0.01, ***P<0.001; one-way ANOVA using plot post-hoc tests (5B, 5C, 5F, 5H, 5J) or Mantel-Cox test (5D).

[0021] Figure 6 The activity of IDO enzyme was measured as the inhibition of kynurenine production after treatment with free 1-MT, 1-MT@NV, and 1-MT@PD-1 NV.

[0022] Figure 7 The fluorescence intensity per gram of tumor tissue at different time points is shown (n=3). Error bars, mean ± standard deviation.

[0023] Figure 8 shows the in vivo inhibitory effect of PD-1 NV loaded with 1-MT on tumor growth. Figure 8A shows in vivo bioluminescence imaging of B16F10 tumors in mice treated with different methods: PBS (Group 1), free Nv (Group 2), 1-MT (Group 3), PD-1 Nv (Group 4), 1-MT@Nv (Group 5), 1-MT+aPD-L1 (Group 6), and 1-MT@PD-1 Nv (Group 7). Day 0: The day of the first treatment. Figure 8B shows the mean tumor volume (n=7) in the different treatment groups as shown. Error bars, mean ± standard error. Figure 8C shows the survival curves of mice treated with different methods as shown (n=10). Figures 8D and 8E show representative flow cytometry plots (8D) and quantitative analysis (dE) of T cells in tumors of different treatment groups. Pre-gated cells were used for CD3-positive cells. + Expression. Error bars, mean ± standard deviation. Figure 8F The image shows the infiltrated CD4. + T cells and CD8 + Immunofluorescence of tumor T cells. Scale bar: 100 μm. Overall, NS: no significant difference, *P<0.05, **P<0.01, ***P<0.001; two two-way ANOVAs were performed for the analyses described (8B and 8E). A first two-way ANOVA was performed between the groups free NV (G2), PD-1 NV (G4), 1-MT@NV (G5), and 1-MT@PD1-NV (G7) using the Tuki post-hoc test. The two factors considered were 1-MT and PD-1. A second two-way ANOVA was performed between the groups PBS control (G1), aPD-L1, 1-MT (G3), and aPD-L1+1-MT (G6). The two factors in this model were 1-MT and aPD-L1 (8B and 8E) or the log-rank (Mantel-Cox) test (8C).

[0024] Figures 9A, 9B, and 9C show the production of PD-1-expressing platelets and CD8+. + Schematic diagram of T cell reactivation. Figure 9A shows a schematic diagram of L8057 cell line stably expressing mouse PD-1 and platelet production. Figure 9B shows PD-1-expressing platelets targeting tumor cells within a surgical wound. Figure 9C The demonstration showed that PD-L1 blockers on platelets expressing PD-1 depleted CD8 cells. + T cells are restored to attack tumor cells.

[0025] Figures 10A, 10B, 10C, 10D, 10E, 10F, 10G, 10H, 10I, 10J, and 10K show platelet production and characterization in the stable L8057 cell line expressing PD-1. Figure 10A shows a confocal image of the L8057 cell line stably expressing mouse EGFP-PD-1 on its cell membrane. The cell membrane was stained with WGA Alexa-Fluor 594 dye (scale bar: 10 μm). Figure 10B shows Western blot analysis used to assess PD-1 expression in the L8057 cell line. L8 is an abbreviation for L8057 cells. Figure 10C shows L8057 cells expressing EGFP-PD-1 stimulated with 500 nm PMA for 3 days, followed by immunostaining to detect Cd42a expression. Figure 10D shows L8057 cells stimulated with 500 nM PMA for 3 days and stained with Wright-Giemsa dye (scale bar: 10 μm). Figure 10E shows the evolution of PD-1-expressing preplatelets extending from MK (scale bar: 10 μm). Figure 10F shows the morphology of PD-1-expressing preplatelets extending from L8057 cells after 6 days of stimulation with 500 nM PMA. PD-1-expressing preplatelets extending from L8057 cells (scale bar: 10 μm). Figure 10G shows a representative confocal image of purified PD-1-expressing platelets (scale bar: 10 μm). Figure 10H shows the size distribution of PD-1-expressing platelets as measured by DLS. Figure 10I shows a CSEM image illustrating the morphology of PD-1-expressing platelets (scale bar: 1 μm). Figure 10J shows a representative TEM image illustrating the morphology and size of PD-1-expressing platelets (scale bar: 1 μm). Figure 10K This shows the number of platelets released from L8057 cells expressing PD-1 after stimulation with 500 nM PMA (n=5).

[0026] Figures 11A, 11B, 11C, 11D, 11E, 11F, 11G, 11H, and 11I show the in vitro and in vivo biological behavior of PD-1 platelets. Figures 11A and 11B show the retention of platelets on collagen-coated or uncoated tissue culture slides. Scale bar, 50 μm. Figure 11C shows confocal, CSEM, and TEM images of thrombin-stimulated PD-1 platelets. Platelet microparticles (PMPs) are released from platelets. Figure 11D shows the measurement of PD-1 platelet size distribution after activation by thrombin treatment for 30 minutes. PMPs are produced from platelets. Figure 11E shows EGFP-PD-1 platelets bound to the B16F10 cell membrane. Cy5.5-labeled PD-1 platelets or free platelets were incubated with B16F10 cells for 20 h. B16F10 cell membranes were stained with WGA Alexa Fluor 594 dye (scale bar: 10 μm). Figure 11F shows B16F10 cells transfected with DsRed-PD-L1 plasmid for 20 h, followed by incubation with EGFP-PD-1 platelets for 5 h, with colocalization of EGFP-PD-1 platelets with DsRed-PD-L1 detected (scale bar: 10 μm). Figure 11G shows Cy5.5-labeled free platelets and PD-1 platelets injected via mouse tail vein. Fluorescence was measured at different time points as shown (n=3). Error bars, mean ± standard deviation. Figure 11H shows in vivo fluorescence images of the distribution of free platelets and PD-1 platelets in major organs and residual tumors. Figure 11I The fluorescence intensity per gram of tissue in the major organs and tumors is shown (n=3). Error bars, mean ± standard deviation.

[0027] Figures 12A, 12B, 12C, 12D, 12E, 12F, 12G, 12H, and 12I show the inhibition of tumor progression by PD-1 platelets in an incompletely resected tumor model. Figure 12A shows a schematic diagram of PD-1 platelets used as a therapy in the incompletely resected tumor model. Figure 12B shows in vivo bioluminescence imaging of B16F10 tumors derived from surgical mice receiving different treatments: PBS, free platelets, and PD-1 platelets, respectively. Figure 12C shows the mean tumor volume of the different groups of mice as shown. Data are presented as mean ± standard deviation. Figure 12D shows the survival curves of the mice receiving different treatments as shown. Figure 12E shows the CD4+... + T cells and CD8 + Immunofluorescence of tumor sections infiltrated with T cells (scale bar: 100 μm). Figures 12F and 12G show the immunofluorescence of tumor sections infiltrated by T cells via flow cytometry (gated to CD3). + Representative curves (12F) and quantitative plots (12G) of T cells in tumors from different treatment groups analyzed by flow cytometry (gated to CD8). Figures 12H and 12I show the T cells obtained by flow cytometry (gated to CD8).+ CD8+ of tumors in different treatment groups analyzed on T cells + Representative curves (12H) and quantitative plots (12I) of GzmB in T cells. Overall, NS: no significant differences, *P<0.05, **P<0.01, ***P<0.001; the analyses described were performed using one-way ANOVA with post-hoc graphical tests (12C, 12G, and 12I) or the log-rank (Mantel-Cox) test (12D).

[0028] Figures 13A, 13B, 13C, 13D, 13E, 13F, 13G, 13H, 13I, 13J, and 13K show the in vivo antitumor effect of PD-1-expressing platelets loaded with cyclophosphamide in an incompletely operated tumor model. Figure 13A shows the mean tumor volume in mice (n=8) treated with: PBS (G1), cyclophosphamide (CP) (G2), PD-1-expressing platelets (G3), CP-free platelets (G4), and CP-loaded PD-1-expressing platelets (G5). Data are presented as mean ± standard deviation. ***Comparison with PBS control. Figure 13 shows the survival curves of the treated mice. Figure 13C shows the effect of flow cytometry (gated to CD4) on the tumor. + Intratumor CD4 (analyzed on T cells) + Quantitative mapping of FoxP3 in T cells (n=3). Figures 13D and 13E show the results of flow cytometry (gated to CD8). + Intratumor CD8 (analyzed on T cells) + Representative curves (13D) and quantitative plots (13E) of Ki67 in T cells (n=3). Figures 13F and 13G show the results obtained by flow cytometry (gated to CD3). + Intratumor CD8 (analyzed on T cells) + and CD4 + Representative curves (13F) and quantitative plots (13G) of T cells (n=3). Figures 13H and 13I show the results of flow cytometry (gated to CD8). + Intratumor CD8 (analyzed on T cells) + Representative curves (13H) and quantitative plots (13I) of GzmB in T cells (n=3). Figures 13J and 13K show CD8... + Immunofluorescence of T-cell infiltrated tumors (scale bar: 100 μm). Overall, NS: no significant difference, *P<0.05, **P<0.01, ***P<0.001; the above analyses were performed using two-way ANOVA with post-hoc graphical tests (13A, 13C, 13E, 13G, 13I, 13K) or the log-rank (Mantel-Cox) test (13B).

[0029] Figures 14A, 14B, and 14C show the growth of B16F10 tumors in mice treated with PD-1-expressing platelets after partial tumor resection. Figure 14A shows in vivo tumor bioluminescence of B16F10 tumors. Figure 14B shows the growth of B16F10 tumors via flow cytometry (gated to CD4). + Intratumor CD4 (analyzed on T cells) + Representative curves of FoxP3 expression in T cells (n=3). Figure 14C Showing the body weight of treated and control mice. Error bars, ± standard deviation. Detailed Implementation

[0030] Before disclosing and describing the compounds, compositions, articles, devices, and / or methods of the present invention, it should be understood that, unless otherwise specified, they are not limited to specific synthetic methods or specific recombinant biotechnology methods, or, unless otherwise specified, they are not limited to specific reagents, as they will certainly vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0031] A. Definition

[0032] As used in the specification and appended claims, the singular forms “a,” “an,” “the,” and “the” include plural references unless the context clearly indicates otherwise. Thus, for example, a reference to “drug carrier” includes a mixture of two or more such carriers, etc.

[0033] A range may be expressed herein as from “about” a particular value and / or to “about” another particular value. When expressing such a range, another embodiment includes from one particular value and / or to another particular value. Similarly, when using the preceding word “about” to represent a value as an approximation, it should be understood that the particular value forms another embodiment. It should also be understood that the endpoints of each range are significant relative to and independent of another endpoint. It should also be understood that numerous values ​​are disclosed herein, and each value is disclosed herein as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, “about 10” is also disclosed. It should also be understood that when “less than or equal to” values ​​and “greater than or equal to” values ​​are disclosed, possible ranges between values ​​as appropriately understood by those skilled in the art are also disclosed. For example, if the value “10” is disclosed, “less than or equal to 10” and “greater than or equal to 10” are also disclosed. It should also be understood that throughout the application, data is provided in a variety of different formats, and this data represents endpoints and starting points, as well as ranges of any combination of data points. For example, if specific data point "10" and specific data point 15 are disclosed, it should be understood that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15, as well as those between 10 and 15, are disclosed. It should also be understood that each cell between the two specific cells is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.

[0034] "Administration" to a subject includes any route by which a drug is introduced or delivered to the subject. Administration can be made by any suitable route, including oral, local, intravenous, subcutaneous, percutaneous, transdermal, intramuscular, intra-articular, parenteral, intra-arterial, intradermal, intravenous, intracranial, intraperitoneal, intralesional, intranasal, rectal, vaginal, by inhalation, by implanted receptacle, parenteral (e.g., subcutaneous, intravenous, intra-articular, intrasynovial, intrasternal, intrathecal, intraperitoneal, intrahepatic, intralesional, and intracranial injection or infusion techniques), etc. As used herein, "parallel administration," "combined administration," or "simultaneous administration" (or "administered simultaneously") means that the compounds are administered at the same time point or substantially immediately afterward. In the latter case, the administration times of the two compounds are close enough that the observed results are indistinguishable from those obtained when the compounds are administered at the same time point. Systemic administration refers to a route that introduces or delivers a drug to a subject by means of a wide area of ​​the subject's body (e.g., more than 50% of the body), such as by means of entry into the circulatory or lymphatic system. In contrast, local administration refers to the introduction or delivery of a drug to a subject through a route that introduces or delivers the drug to one or more areas immediately adjacent to the point of administration, and the drug is not introduced in a large, unsystematic manner for therapeutic purposes. For example, a locally administered drug may be readily detectable in the vicinity of the point of administration, but may be undetectable or detectable in negligible amounts in distal parts of the subject's body. Administration includes self-administration and administration by another person.

[0035] "Biocompatible" generally means that the material and any of its metabolites or degradation products are generally non-toxic to the subjects and do not cause significant side effects to the subjects.

[0036] "Comprising" means that a composition, method, etc., includes the mentioned elements, but does not exclude other elements. When used to define compositions and methods, "consistently composed of" should mean including the mentioned elements, but excluding other elements that are of any significance to the composition. Therefore, a composition consisting essentially of the elements defined herein does not exclude trace contaminants from separation and purification methods and pharmaceutically acceptable carriers, such as phosphate-buffered saline, preservatives, etc. "Containing" should mean excluding trace elements more than other components and substantial method steps used to give the compositions of the present invention. Examples defined by each of these transitional terms are within the scope of the present invention.

[0037] A "control" is a substitute subject or sample used for comparison purposes in an experiment. A control can be a "positive control" or a "negative control".

[0038] "Controlled release" or "sustained release" refers to the controlled release of a drug from a given dosage form in order to achieve the desired pharmacokinetic profile in vivo. One aspect of "controlled release" drug delivery is the ability to manipulate the formulation and / or dosage form to establish the desired drug release kinetics.

[0039] The “effective amount” of a drug refers to the sufficient quantity of the drug to provide the desired effect. The amount of “effective” drug will vary among subjects, depending on many factors such as the subject’s age and general condition, the specific drug or one or more, and so on. Therefore, it is not always possible to specify a quantifiable “effective amount.” However, the appropriate “effective amount” in any subject’s case can be determined by a person skilled in the art using standard experimental methods. Furthermore, as used herein, and unless otherwise specifically stated, the “effective amount” of a drug may also refer to an amount that encompasses both therapeutic and preventative effective amounts. The “effective amount” of a drug required to achieve a therapeutic effect can vary based on factors such as the subject’s age, sex, and weight. Dosing regimens can be adjusted to provide the best therapeutic response. For example, several separate doses may be administered daily, or the dose may be reduced proportionally according to the urgency of the treatment situation.

[0040] "Pharmaceutical acceptable" means a component that is not biologically or otherwise undesirable, i.e., that the component can be incorporated into the pharmaceutical formulation of the present invention and administered to subjects as described herein without causing significant adverse biological effects or interacting harmfully with any other component of the formulation containing the component. When used to refer to administration to humans, this term generally means that the component has met the requirements of toxicological and manufacturing testing, or that it is included in the inactive ingredient guidelines established by the U.S. Food and Drug Administration.

[0041] "Pharmaceutically acceptable carrier" (sometimes referred to as "carrier") means a carrier or excipient that can be used to prepare a pharmaceutical or therapeutic composition that is generally safe and non-toxic, and includes pharmaceutically acceptable carriers for veterinary and / or human pharmaceutical or therapeutic use. The term "carrier" or "pharmaceutically acceptable carrier" can include, but is not limited to, phosphate-buffered saline solutions, water, emulsions (such as oil / water or water / oil emulsions), and / or various types of wetting agents. As used herein, the term "carrier" includes, but is not limited to, any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, or other materials well known in the art for use in pharmaceutical formulations, and as further described herein.

[0042] "Pharmacological activity" (or simply "activity"), as used in "pharmacologically active" derivatives or analogs, can refer to derivatives or analogs that have the same type of pharmacological activity as the parent compound and are substantially equal in degree (e.g., salts, esters, amides, conjugates, metabolites, isomers, fragments, etc.).

[0043] "Polymer" refers to a relatively high molecular weight natural or synthetic organic compound whose structure can be represented by repeating small units or monomers. Non-limiting examples of polymers include polyethylene, rubber, and cellulose. Synthetic polymers are typically formed by the addition or condensation polymerization of monomers. The term "copolymer" refers to a polymer formed from two or more different repeating units (monomer residues). By way of example and without limitation, copolymers can be alternating copolymers, random copolymers, block copolymers, or graft copolymers. It is also conceivable that, in some aspects, the various block segments of a block copolymer may themselves comprise the copolymer. The term "polymer" includes all forms of polymers, including but not limited to natural polymers, synthetic polymers, homopolymers, hybrids, or copolymers, addition polymers, etc.

[0044] "Therapeutic agent" means any composition having a beneficial biological effect. Beneficial biological effects include therapeutic and preventative effects, where a therapeutic effect is, for example, the treatment of a disorder or other undesirable physiological condition, and a preventative effect is, for example, the prevention of disease or other adverse physiological symptoms (e.g., non-immunogenic cancer). The term also covers pharmaceutically acceptable pharmacologically active derivatives of the beneficial agents specifically mentioned herein, including, but not limited to, salts, esters, amides, prodrugs, active metabolites, isomers, fragments, analogs, etc. When the term "therapeutic agent" is used, or when a specific pharmaceutical agent is explicitly identified, it should be understood that the term includes the agent itself as well as pharmaceutically acceptable pharmacologically active salts, esters, amides, prodrugs, conjugates, active metabolites, isomers, fragments, analogs, etc.

[0045] The "therapeutic effective amount" or "therapeutic effective dose" of a composition (e.g., a composition comprising a pharmaceutical agent) refers to the amount that effectively achieves the desired therapeutic outcome. In some embodiments, the desired therapeutic outcome is control of type 1 diabetes. In some embodiments, the desired therapeutic outcome is control of obesity. The therapeutically effective amount of a given therapeutic agent will generally vary depending on factors such as the type and severity of the disorder or disease being treated, and the subject's age, sex, and weight. The term may also refer to the amount of therapeutic agent that effectively promotes the desired therapeutic effect (e.g., pain relief) or the rate of delivery of the therapeutic agent (e.g., the amount over time). The precise desired therapeutic effect will vary depending on the condition being treated, the subject's tolerance, the pharmaceutical agent and / or pharmaceutical formulation to be administered (e.g., the potency of the therapeutic agent, the concentration of the pharmaceutical agent in the formulation, etc.), and various other factors understood by those skilled in the art. In some cases, the desired biological or medical response may be obtained after administering multiple doses of the composition to a subject for several consecutive days, weeks, or years.

[0046] In this specification and the following claims, several terms will be referenced and defined to have the following meanings:

[0047] "Optional" or "optionally" means that the event or situation described below may or may not occur, and the description includes both the scenario in which the event or situation occurs and the scenario in which the event or situation does not occur.

[0048] Throughout this application, various publications have been cited. The full disclosure of these publications is incorporated herein by reference in order to provide a more comprehensive description of the current state of the art to which this application pertains. Disclosed references are also individually and specifically incorporated herein by reference, and the material contained in the references is discussed in the sentences on which the references are based.

[0049] B. Composition

[0050] This invention discloses methods for preparing the compositions disclosed herein, as well as the compositions themselves used in the methods disclosed herein. These and other materials are disclosed herein, and it should be understood that while specific references to various individual and collective combinations and arrangements of these materials may not be explicitly disclosed when the invention discloses combinations, subsets, interactions, groups, etc., each of these materials is particularly considered and described herein. Thus, if AD is disclosed as a class of molecules A, B, and C and a class of molecules D, E, and F, and examples of combined molecules, then combinations AE, AF, BD, BE, BF, CD, CE, and CF, both individually and collectively considered, are considered disclosed, even without individual reference to each of them. Similarly, any subsets or combinations of these combinations are also disclosed. Therefore, for example, a subgroup of AE, BF, and CE would be considered disclosed. This concept applies to all aspects of this application, including but not limited to the steps in methods for preparing and using the compositions disclosed herein. Therefore, if various additional steps are available, it should be understood that each of these additional steps can be performed using any particular embodiment or combination of embodiments of the methods disclosed herein.

[0051] It is understandable and expected that immunotherapies such as checkpoint inhibitor blockades can effectively treat cancer or recurrence after surgical resection of tumors. However, the antibodies used in these blockades are limited for many patients and ineffective for many more. This article discloses natural cell membrane-derived vesicles, such as exosomes, microvesicles, and cell membrane repulsion vesicles, which have broad biomedical applications. Similarly, bioengineering strategies are promising methods for enhancing anti-tumor immunity. Here, cell membrane-derived nanovesicles (NVs) are engineered to display PD-1 receptors, which enhance cancer immunotherapy by disrupting the PD-1 / PD-L1 immunosuppressive axis (Figure 1a). Likewise, engineered drugs conjugated to anti-PD-L1 can target tumor surgical trauma, revitalizing depleted T cells. Thus, in one aspect, this article discloses engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which can be used as checkpoint blockades in cancer immunotherapy.

[0052] As described above, blockers of immunosuppressive interactions can rescue or prevent T-cell depletion and enable the immune system to clear tumors, and prevent tumor proliferation and / or metastasis, either alone or after surgical resection. Several important immune system blockers are known in the art, including programmed death 1 (PD-1) / programmed death ligand 1 (PDL-1); T-cell immune receptor (TIGIT) / CD155 with Ig and ITIM domains; T-cell immunoglobulin and mucin domain-3 (TIM-3) / galactagogue-9, phosphatidylserine (PtdSer), carcinoembryonic antigen-associated cell adhesion molecule 1 (CEACAM1) or high-mobility group box 1 (HMGB1); and / or lymphocyte activation gene 3 (LAG3) / MHC class II. Therefore, in one aspect, this document discloses engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which can be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, and / or TIM3.

[0053] It is understood and anticipated that the engineered nanovesicles, engineered megakaryocytes, or engineered platelets may be derived from any cell capable of supporting their manufacture, including but not limited to dendritic cells, stem cells, immune cells, megakaryocyte progenitor cells, megakaryocytes, or macrophages. Therefore, in one aspect, this document discloses engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which can be used as checkpoint blockers in cancer immunotherapy, wherein the engineered nanovesicles, engineered megakaryocyte progenitor cells, or engineered platelets are derived from dendritic cells, stem cells, immune cells, megakaryocyte progenitor cells, or macrophages.

[0054] 1. Delivery of drug carriers / drugs

[0055] In one aspect, it should be understood that the engineered nanovesicles, engineered megakaryocytes, or engineered platelets described herein are intended to be administered to a subject to treat, prevent, inhibit, or reduce cancer or metastasis, or to treat, prevent, inhibit, or reduce recurrence or metastasis following surgical resection (i.e., excision). Therefore, pharmaceutical compositions comprising the engineered nanovesicles, engineered megakaryocytes, or engineered platelets disclosed herein are disclosed herein. For example, pharmaceutical compositions comprising engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors are disclosed herein, which may be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3.

[0056] In one respect, it is understood and anticipated that other inhibitors of other immunomodulatory pathways, when combined with the disclosed engineered nanovesicles, engineered megakaryocytes, and engineered platelets, could provide additional benefits for cancer treatment. For example, indoleamine 2,3-dioxygenase (IDO) inhibitors, combined with, for example, 1-methyltryptophan (1-MT), can enhance the immune response against cancer. Similarly, anti-PDL-1 antibodies (such as, for example, nivolumab, pembrolizumab, pidilizumab, BMS-936559, atezolizumab, durvalumab, and avelumab) can bind to any PDL-1 that engineered nanovesicles, engineered megakaryocytes, or engineered platelets have failed to bind. Therefore, this document discloses pharmaceutical compositions comprising engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which can be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3, and the pharmaceutical compositions further comprising one or more therapeutic agents, such as, for example, small molecules (including but not limited to 1-methyl-tryptophan (1-MT), desmethylhalamine, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vincristine, cyclophosphamide, and 5-fluorouracil), siRNA, peptides, peptide mimics, or antibodies (such as, for example, and anti-PDL-1 antibodies, including but not limited to nivolumab, pembrolizumab, abavoxel, BMS-936559, atezolizumab, durvalumab, and avelumab).

[0057] The one or more therapeutic agents may be provided in a pharmaceutical composition together with the engineered nanovesicles, engineered megakaryocyte progenitor cells, or engineered platelets. Alternatively, the one or more therapeutic agents may be encapsulated within the engineered nanovesicles, engineered megakaryocyte progenitor cells, or engineered platelets. Therefore, in one aspect, this document discloses pharmaceutical compositions comprising engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which can be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3, and the pharmaceutical composition further comprises one or more therapeutic agents, such as, for example, small molecules (including but not limited to 1-methyl-tryptophan (1-MT), desmethylhalamine, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vincristine, cyclophosphamide, and 5-fluorouracil), siRNA, peptides, peptide mimics, or antibodies (such as, for example, and anti-PDL-1 antibodies, including but not limited to nivolumab, pembrolizumab, abavoxel, BMS-936559, atezolizumab, durvalumab, and avelumab); and wherein the one or more therapeutic agents are encapsulated in the engineered nanovesicles, engineered megakaryocytes, or engineered platelets.

[0058] Since the disclosed pharmaceutical compositions, including the disclosed engineered nanovesicles, engineered megakaryocytes, or engineered platelets, can be used to treat cancer, it is also anticipated that the disclosed pharmaceutical compositions may further include any known chemotherapy therapies known in the art, including but not limited to abemaciclib, abiraterone acetate, abitrexate (methotrexate), abraxane (paclitaxel albumin-stabilized nanoparticles), ABVD, ABVE, ABVE-PC, AC, AC-T, adcetris (Brentuximab Vedotin), ADE, ado-trastuzumab emtansine conjugate, doxorubicin (doxorubicin hydrochloride), and afatinib maleate. Dimaleate, Afinitor (everolimus), Akynzeo (netupitant and palonosetron hydrochloride), Aldara (imiquimod), Aldesleukin, Alecensa (alectinib), Alemtuzumab, Alimta (pemetrexed disodium), Aliqopa (copanlisib) Hydrochloride, Alkeran (Melphalan Hydrochloride) for injection, Alkeran tablets (Melphalan), Aloxi (palonosetron hydrochloride), Alunbrig (Brigatinib), Ambochlorin (Chlorambucil), Amboclorin (Chlorambucil), Amifostine, Aminolevulinic Acid, Anastrozole, Acrepitant, Aredia (Pamidronate Disodium), Reninide (Anastrozole), Anorexin (Exemestane), Arranon (Nelarabine), Arsenic trioxide, Arzerra (Olfamumab), Asparaginase ErwiniaChrysanthemi), Atezolizumab, Avastin (bevacizumab), Averuzumab, Axitinib, Azacitidine, Bavencio (averuzumab), BEACOPP, Becenum (carmustine), Beleodaq (belindustat), Belindustat, Bendamustine Hydrochloride, BEP, Besponsa (iogamicin), Bevacizumab, Besalotine, Bexxar (tositummomab and iodine I-131 tositummomab), Bicalutamide, BiCNU (carmustine), Bleomycin, Lantumomab, Blincyto (lantumomab), Bortezomib, Bosulif (bosutinib), Bosutinib, Brentuximab Vedotin, Brigatinib, BuMel, Busulfan, Busulfex, Cabozantinib, Cabometyx, Cabozantinib S-Malate, CAF, Calquence (Acalabrutinib), Camptosar (Irinotecan Hydrochloride), Capecitabine (Cap... ecitabine), CAPOX, fluorouracil (Carac) (fluorouracil for external use), carboplatin, carboplatin-paclitaxel, carfilzomib, carmustine (Carmustine), carmustine implants, Casodex (bicalutamide), CEM, ceritinib, daunorubicin (daunorubicin hydrochloride) Hydrochloride, Cervarix (recombinant bivalent HPV vaccine), Cetuximab, CEV, Chloramic acid mustard, Chloramic acid mustard-prednisone, CHOP, Cisplatin, Claribine, Cyclophosphamide, Clofarex, Clolar, CMF, Cobimetinib, Cometriq (cabozotinib malate), CopanlisibHydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen (Dactinomycin D), Cotellic (Cobimetinib), Crizotinib, CVP, Cyclophosphamide, Cyfos (Ifosfamide), Cyramza (Ramucab), Cytarabine, Cytarabine Liposome Liposome, Cytoxan U (cytarabine), Cyclophosphamide, Dabrafenib, Dacarbazine, Dacogen (decitabine), Actinomycin D, Darazalex, Dasatinib, Dazorubicin Hydrochloride, Dazorubicin Hydrochloride and Cytarabine Liposome, Decitabine, Defibrinoside Sodium, Defitelio (defibrinoside Sodium), Degarelix, Denisulin-2, Denosumab, Liposome Cytarabine (Depo) Cyt (cytarabine liposome), dexamethasone, dextromethorphan hydrochloride, dinutuximab, docetaxel, doxil (doxorubicin hydrochloride liposome), doxorubicin hydrochloride, dox-SL (doxorubicin hydrochloride liposome), DTIC-Dome (dacarbazine), durvalumab, fluorouracil (Efudex) (fluorouracil for external use), Elitek (raburicase), epirubicin hydrochloride (Ellence) (epirarubicin hydrochloride) Hydrochloride, elexizumab, oxaliplatin (oxaliplatin), eltrombopag (eltrombopag), enend (aprepitant), empliciti (elexizumab), enasidenib mesylate, enzalutamide, epirubicin hydrochloride, EPOCH, erbitux (cetuximab), erribulin mesylateMesylate), Erivedge (Vismodegib), Erlotinib Hydrochloride, Erwinaze (Erwinia asparaginase), Ethyol (Amifostine), Vanbex (etoposide phosphate), Etoposide, Etoposide phosphate, Doxorubicin Liposome (Doxorubicin Hydrochloride Liposome), Everolimus, Evita (Raloxifene Hydrochloride), Evomela (Melphalan Hydrochloride), Esimerme Tan, 5-FU (fluorouracil injection), 5-FU (fluorouracil - topical), Faretine (toremifene), Farydak (pabistat), Faslodex (fulvestrant), FEC, Flon (letrozole), Figex, Fodora (fludarabine phosphate), Fludarabine phosphate, Fluoroplex (fluorouracil - topical), Fluoroplex injection, Fluoroplex - topical, Flutamide, Foles (methotrexate), Foles PFS (Methotrexate), FOLFIRI, FOLFIRI-Bevacizumab, FOLFIRI-Cetuximab, FOLFIRINOX, FOLFOX, Folotyn (Platratolexa), FU-LV, Fulvestrant, Gardasil (Recombinant HPV Quadrivalent Vaccine), Gardasil 9 (Recombinant HPV 9-valent Vaccine), Gazyva (Atocilizumab), Gefitinib, Gemcitabine Hydrochloride, Gemcitabine-Cisplatin, Gemcitabine-Oxaliplatin, Giemzaptamethasone (Ozomicin), Gemzar (Gemcitabine Hydrochloride), Gilotrif (Afatinib Maleate), Afatinib (Imatinib Mesylate), Gliadel (Carmustine Implant), Gliadel Chip (Carmustine Implant), Guka Pyramidase, Cyclocarpine acetate, Halaven (Eribulin mesylate), Hemangeol (Propranolol hydrochloride), Herceptin (Trastuzumab), Recombinant HPV bivalent vaccine, Recombinant HPV nine-valent vaccine, Recombinant HPV quadrivalent vaccine, Topotecan hydrochloride, Hydroxyurea, Hydroxyurea, Hyper-CVAD, Ibrance (Palbociclib), Imoxicillin, Ibrutinib, ICE, Iclusig (Ponatinib Hydrochloride), IdarubicinHydrochloride, Idarubicin hydrochloride, Idelalisib, Idhifa (ensildenafil mesylate), Ifex (ifosfamide), ifosfamide, pifampin (ifosfamide), IL-2 (aldeleukin), imatinib mesylate, Ibrutinib (Ibruvica), Imfinzi (durvalumab), imiquimod, Imlygic (Talimogene Laherparepvec), Inlyta (axitinib), ozogamicin, recombinant interferon α-2b, interleukin-2 (aldeleukin), intron A (recombinant interferon α-2b), iodine I 131. Tosimomumab and Ipilimumab, Iressa (Gefitinib), Irinotecan Hydrochloride, Irinotecan Hydrochloride Liposome, Istodax (Romidix), Ixapoxone, Ixazomib Citrate, Ixempra (Ixapoxone), Jakafi (Ruxolitinib Phosphate), JEB, Jevtana (Cabbathax), Kadcyla (Trastuzumab-Mestane conjugate), Raloxifene (Keoxifene) (Raloxifene Hydrochloride) Hydrochloride, Keytruda (Pembrolizumab), Kisqali (Ribociclib), Kymriah (Tisagenlecleucel), Kyprolis (Carfilzomib), Lanreotide Acetate, Lapatinib Toluenesulfonate, Lartruvo (Olaratumab), Lenalidomide, Lenvatinib Mesylate Mesylate), Lenvima (lenvatinib mesylate), letrozole, leucovorin calcium, leucoran (chlorambucil), leuprolide acetate, cladribine, levulan (aminolevulinic acid), linfolizin (chlorambucil), LipoDox (doxorubicin hydrochloride liposomes), lomustine, Lonsurf (trifluuridine and tipiracil hydrochloride), leuprolide acetate, leuprolide acetate depot (Lupron Depot), leuprolide acetate suspension.Depot-Ped (Leuprorelin Acetate), Lynparza (Olaparib), Marqibo (Vincristine Sulfate Liposome), Procarbazine Hydrochloride (Matulane), Nitrogen Mustard Hydrochloride, Medroxyprogesterone Acetate, Mekinist (Trametinib), Melphalan, Melphalan Hydrochloride, Mercaptopurine, Mesna, Mesna (Mesna) ), temozolomide (Temozolomide), methotrexate, methotrexate LPF (methotrexate), bromomethyl terbutaline, methotrexate sodium (Mexate) (methotrexate), methotrexate sodium-AQ (methotrexate), midottolin, mitomycin C, mitoxantrone hydrochloride, mitozytrex (mitomycin C), MOPP, Mozobil (prexafo), nitrogen mustard (nitrogen mustard hydrochloride), mitomycin (mitomycin C), busulfan ( Busulfan, Mylosar (azacitidine), Merota (gimenizumab ozomicin), paclitaxel nanoparticles (paclitaxel albumin-stabilized nanoparticle formulation), Noviban (vinorelbine tartrate), Nexilimumab, Nerabin, Cyclophosphamide (Neosar) (Cyclophosphamide), Nerlynx (Neratinib maleate), Netopitant and Palosetron Hydrochloride, Neulasta (pefexazone), Ubuprofen (filgrastim), Sorafenib (Nexavar) Sorafenib tosylate, Nilandron, Nilotinib, Nilotinib, Ninlaro (Ixazomib citrate), Niraparib tosylate monohydrate, Nivolumab, Novadex (Tamoxifen citrate), Nplate (Romilastine), Atorizumab, Odomzo (Sonidegib), OEPA, Ofamumab, OFF, Olaparib, Omacetaxine Mepesuccinate, Oncaspar (Pegaspargase), Ondansetron hydrochloride, Onivyde (Irinotecan hydrochloride liposome), Ontak (Denileukin)Diftitox, Opdivo (nivolumab), OPPA, Osimertinib, Oxaliplatin, Paclitaxel, Paclitaxel albumin-stabilized nanoparticle formulation, PAD, Palbociclib, Palivmin, Palosetron hydrochloride, Palosetron hydrochloride and Nettopitan, Pamidronate disodium, Palimumab, Pabistat, Paraplatin (carboplatin), Pazopanib hydrochloride, PCV, PEB, Pegaspargase, Pegfilgrastim, Peginterferon α-2b Alfa-2b), PEG-intron (pegylated interferon α-2b), pembrolizumab, pemetrexed disodium, Perjeta (pertozumab), cisplatin (Platinol), cisplatin-AQ (cisplatin), prasalifos, pomalidomide, pomalyst (pomalidomide), panatinib hydrochloride, Portrazza (neximetumab), prastrexate, prednisone, procarbazine hydrochloride, aldesleukin (aldesleukin), Prolia (denosumab), Promacta (eltrombopag) Olamine, propranolol hydrochloride, Provenge (Sipuleucel-T), purine (Mercaptopurine), purixan, radium-223 dichloride, raloxifene hydrochloride, ramucirumab, raburicase, R-CHOP, R-CVP, recombinant human papillomavirus (HPV) bivalent vaccine, recombinant human papillomavirus (HPV) nonavalent vaccine, recombinant human papillomavirus (HPV) quadrivalent vaccine Recombinant interferon α-2b, regorafenib, Relistor (methylbromotrione), R-EPOCH, Revlimid (lenalidomide), Methotrexate, Ribociclib, R-ICE, Rituxan, RituxanHycela (rituximab and human hyaluronidase), Rituxan, Rituxan and human hyaluronidase, Rorapitan hydrochloride, Romidixin, Romistachytin, Daunorubicin Hydrochloride, Rubracarib (rucaparib)Camsylate, Ricaprablutracetamol, Ruxotinib Phosphate, Rydapt (Midottolin), Sclerosol Intrapleural Aerosol (Talc), Sesutuximab, Sipuleucel-T, Somadulin Depot (Lanretinib Acetate), Sonidegib, Sorafenib Tosylate, Sprycel (Dasatinib), STANFORD V. Sterile talc, Steritalc, Stivarga (regorafenib), Sunitinib malate, Sunitinib malate, Sylatron (pegylated interferon alpha-2b), Sylvant (staxicumab), Synribo (methotrexate), Tabloid (thioguanine), TAC, Tafinlar (dabrafenib), Tagrisso (osimertinib), Talimogene Laherparepvec, Tamoxifen acetate, Tarabine PFS (cytarabine), Tarceva (erlotinib hydrochloride), Targretin (bexarotin), Tasigna (nilotinib), Taxol (paclitaxel), Taxotere (docetaxel), Tecentriq (atezilumab), Temodar (temozolomide), Temozolomide, Tanciolimus, Thalidomide, Thalidomide, Thioguanine, Thiotepa, Tisagenlecleucel, Tolak (fluorouracil - topical), Topotecan hydrochloride, Toremifene, Torisel (tanciolimus), Tosimomab, and Iodine I 131. Tosimomab, Totect (dextramidine hydrochloride), TPF, Trabectedin, Trametinib, Trastuzumab, Treanda (bendamustine hydrochloride), Trifluuridine and Tipiracil Hydrochloride, Arsenic trioxide (Trisenox) (Arsenic trioxide)Trioxide, Tykerb (lapati dibenzylsulfonate), Unituxin (Dinutuximab), uridine triacetate, VAC, vandetanib, VAMP, Varubi (rorapitan hydrochloride), Vectibix (perumumab), VelP, vincaline sulfate, bortezomib, Velsar (vincaline sulfate), vemurafenib, Venclexta (Venetoclax), Verzenio (abexinib), Viadur (leuprolide acetate), azacitidine (Vidaza), vincaline sulfate, Vincasar PFS (vincaline sulfate injection) Sulfate, vincristine sulfate, vincristine sulfate liposomes, vinorelbine tartrate, VIP, vemodigine, Vistogard (guanosine triacetate), Voraxaze (glutapeptide), vorinsta, Votrient (pazopanib hydrochloride), Vyxeos (daunorubicin hydrochloride and cytarabine liposomes), leucovorin (calcium leucovorin) Calcium), Xalkori (crizotinib), Xeloda (capecitabine), XELIRI, XELOX, Xgeva (denosumab), Xofigo (radium-223 dichloride), Xtandi (enzalutamide), Yervoy (ipilimumab), Yondelis (trabectedine), Zaltrap (aflibercept), Zarxio (filgrastim), Zejula (niraparib tosylate monohydrate), Zelboraf (vemurafenib), Zevalin (teimomab), Zinecard (dexprofen hydrochloride), Ziv-Aflibercept, Zofran (ondansetron hydrochloride), Zoladex (zoledronic acid (Goserelin Acetate)), Zoledronic acid (Zoledronic acid) Acid), Zolinza (volinusta), Zometa (zoledronic acid), Zydelig (edraquinone), Zykadia (cenitinib), and / or Zytiga (abiraterone acetate).

[0059] As described above, these compositions can also be administered in vivo via pharmaceutically acceptable carriers. "Pharmaceutically acceptable" means a material that is not biologically or otherwise undesirable; that is, the material can be administered to a subject together with the nucleic acid or carrier without causing any adverse biological effects or interacting in a harmful manner with any other component of the pharmaceutical composition containing it. As is well known to those skilled in the art, the carrier will naturally be selected to minimize any degradation of the active ingredient and any adverse side effects in the subject.

[0060] The composition can be administered orally, parenterally (e.g., intravenously), intramuscularly, intraperitoneally, percutaneously, externally, and topically, including intranasal administration or administration via inhalation. As used herein, “intranasal administration” means delivery of the composition to the nasal cavity and nasal passages through one or both nostrils, and may include delivery via a spray or droplet mechanism, or via the atomization of a nucleic acid or carrier. Administration of the composition via inhalation is via the nasal cavity or mouth, via a spray or droplet mechanism. Delivery may also be via intubation directly to any area of ​​the respiratory system (e.g., the lungs). The exact amount of composition required varies from subject to subject, depending on the subject’s species, age, weight and general condition, the severity of the allergic disorder being treated, the specific nucleic acid or carrier used, the route of administration, etc. Therefore, it is not possible to specify an exact amount for each composition. However, the appropriate amount can be determined by those skilled in the art through routine experiments using only the teachings given herein.

[0061] Parenteral administration of this composition (if used) is typically characterized by injection. Injectable formulations can be prepared in conventional forms, such as liquid solutions or suspensions, or in solid forms suitable for dissolving the suspension in a liquid prior to injection, or as emulsions. Recently revised parenteral administration methods include the use of sustained-release or sustained-release systems to maintain a constant dose. See, for example, U.S. Patent No. 3,610,795, which is incorporated herein by reference.

[0062] The materials can be solutions or suspensions (e.g., incorporated into microparticles, liposomes, or cells). They may target specific cell types via antibodies, receptors, or receptor ligands. The following references are examples of using this technique to target specific proteins to tumor tissues (Senter et al., Bioconjugate Chem., 2:447-451, (1991); Bagshawe, KD, Br.J. Cancer, 60:275-281, (1989); Bagshawe et al., Br.J. Cancer, 58:700-703, (1988); Senter et al., Bioconjugate Chem., 4:3-9, (1993); Battelli et al., Cancer Immunol. Immunother., 35:421-425, (1992); Pietersz and McKenzie, Immunolog. Reviews, 129:57-80, (1992); and Roffler et al., Biochem. Pharmacol, 42:2062-2065, (1991)). "Stealth" and other antibody-conjugated liposomes (including lipid-mediated drugs for colon cancer), receptor-mediated DNA targeting via cell-specific ligands, lymphocyte-mediated tumor targeting, and highly specific therapeutic retroviral targeting of mouse glioma cells in vivo are all vectors. The following references provide examples of using this technology to target specific proteins to tumor tissues (Hughes et al., Cancer Research, 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophysica Acta, 1104:179-187, (1992)). Generally, receptors participate in endocytosis, whether constitutively or ligand-induced. These receptors aggregate in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through acidified endosomes that classify receptors, then circulate to the cell surface, are stored intracellularly, or are degraded in lysosomes. Internalization pathways have multiple functions, including nutrient absorption, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, ligand dissociation and degradation, and regulation of receptor levels. Depending on cell type, receptor concentration, ligand type, ligand valence state, and ligand concentration, many receptors follow more than one intracellular pathway. This review summarizes the molecular and cellular mechanisms of receptor-mediated endocytosis (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).

[0063] a) Pharmaceutically acceptable carriers

[0064] The composition includes antibodies that can be used in combination with a pharmaceutically acceptable carrier for therapeutic purposes.

[0065] Remington: The Science and Practice of Pharmacy (19th Edition), ARGennaro, Mack Publishing Company, Easton, PA 1995, describes suitable carriers and their formulations. Typically, an appropriate amount of pharmaceutically acceptable salt is used in the formulation to make it isotonic. Examples of pharmaceutically acceptable carriers include, but are not limited to, physiological saline, Ringer's solution, and glucose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained-release formulations, such as semi-permeable membrane matrices of solid hydrophobic polymers containing antibodies, wherein the matrix is ​​in the form of a molded article, such as a membrane, liposome, or microparticle. It will be apparent to those skilled in the art that certain carriers may be more preferable, for example, depending on the route of administration and the concentration of the administration composition.

[0066] Drug carriers are known to those skilled in the art. These are typically standard carriers for administering drugs to humans, including solutions such as sterile water, physiological saline, and buffer solutions at physiological pH. These compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.

[0067] The pharmaceutical composition may include a carrier, thickener, diluent, buffer, preservative, surfactant, and selected molecules. The pharmaceutical composition may also include one or more active ingredients, such as antibacterial agents, anti-inflammatory agents, anesthetics, etc.

[0068] Depending on whether local or systemic treatment is required and the treatment area, the pharmaceutical composition can be administered in a variety of ways. Administration can be local (including ocular, vaginal, rectal, and intranasal), oral, inhalation, or parenteral, such as intravenous infusion, subcutaneous, intraperitoneal, or intramuscular injection. The disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavitarily, or percutaneously.

[0069] Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents include propylene glycol, polyethylene glycol, vegetable oils (such as olive oil), and injectable organic esters (such as ethyl oleate). Aqueous carriers include water, alcohol / aqueous solutions, emulsions, or suspensions, including physiological saline and buffer media. Parenteral carriers include sodium chloride solutions, Ringer's glucose, glucose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous carriers include liquids and nutritional supplements, electrolyte supplements (such as Ringer's glucose-based supplements), etc. Preservatives and other additives may also be present, such as antibacterial agents, antioxidants, chelating agents, and inert gases.

[0070] Topical drug delivery formulations may include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids, and powders. Traditional drug carriers, water, powders, or oily bases, thickeners, etc., may be necessary or desirable.

[0071] Oral administration compositions include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersants, or binders may be preferred.

[0072] Some compositions can be potentially administered as pharmaceutically acceptable acid or base addition salts and are formed by the reaction of inorganic acids (such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanate, sulfuric acid, and phosphoric acid) with organic acids (such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, maleic acid, and fumaric acid), or by the reaction of inorganic bases (such as sodium hydroxide, ammonium hydroxide, and potassium hydroxide) with organic bases (such as mono-, di-, and trialkyl and arylamines and substituted ethanolamines).

[0073] b) Therapeutic uses

[0074] The effective dosage and schedule for administering the composition can be determined empirically, and such determination is within the scope of the art. The dosage range of the composition should be sufficiently wide to produce the desired effect, thereby affecting the symptoms of the disorder. The dosage should not be too high to cause adverse side effects, such as unwanted cross-reactions, allergic reactions, etc. Generally, the dosage will vary depending on the patient's age, condition, sex, and severity of the disease, as well as the route of administration or whether other medications are included in the regimen, and can be determined by someone skilled in the art. If there are any contraindications, the dosage can also be adjusted by an individual physician. The dosage can be varied and can be administered once or multiple times daily for one or several days. For a given class of medicines, guidelines for appropriate dosages can be found in the literature. For example, guidelines for selecting appropriate antibody doses can be found in the literature on antibody therapeutic uses, such as Handbook of Monoclonal Antibodies, edited by Ferrone et al., Noges Publications, Park Ridge, NJ, (1985), Chapter 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, edited by Haber et al., Raven Press, New York (1977), pp. 365-389. Based on the above factors, the typical daily dose of an antibody used alone may range from approximately 1 μg / kg to 100 mg / kg body weight or more per day.

[0075] 2. Methods of treating cancer

[0076] As described herein, the disclosed engineered nanovesicles, engineered megakaryocytes, engineered platelets, and / or pharmaceutical compositions can be used to treat any disease in which uncontrolled cell proliferation occurs, such as cancer. Therefore, in one aspect, this document discloses the treatment, reduction, inhibition, or prevention of cancer (including, but not limited to, melanoma, renal cell carcinoma, non-small cell lung cancer, and / or bladder cancer) in a subject; proliferation of cancer (including, but not limited to, melanoma, renal cell carcinoma, non-small cell lung cancer, and / or bladder cancer); metastasis of cancer (including, but not limited to, melanoma, renal cell carcinoma, non-small cell lung cancer, and / or bladder cancer); and / or the treatment, reduction, inhibition, or prevention of recurrence, proliferation, or metastasis of tumors (including, but not limited to, melanoma, renal cell carcinoma, non-small cell lung cancer, and / or bladder cancer) after surgical resection, comprising administering to a cancer patient the engineered nanovesicles, engineered megakaryocytes, engineered platelets, and / or pharmaceutical compositions disclosed herein. Therefore, in one aspect, this document discloses methods for treating, reducing, inhibiting, or preventing cancer in a subject; cancer proliferation; cancer metastasis; and / or treating, reducing, inhibiting, or preventing cancer recurrence, proliferation, or metastasis after surgical resection of a tumor, comprising administering to a subject engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which (or pharmaceutical compositions comprising them) may be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3. It will be understood that the engineered nanovesicles, engineered megakaryocytes, engineered platelets, and / or pharmaceutical compositions used in the disclosed methods may further include one or more therapeutic agents to enhance the immunotherapeutic effect of the engineered nanovesicles, engineered megakaryocytes, engineered platelets, and / or pharmaceutical compositions. For example, the engineered nanovesicles, engineered megakaryocytes, engineered platelets, and / or pharmaceutical compositions used in the disclosed methods may further comprise small molecules (including, but not limited to, 1-methyl-tryptophan (1-MT), desmethylhalamine, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vincristine, cyclophosphamide, and 5-fluorouracil), siRNA, peptides, peptide mimics, or antibodies (such as, for example, and anti-PDL-1 antibodies, including but not limited to nivolumab, pembrolizumab, abavoxel, BMS-936559, atezolizumab, durvalumab, and avelumab). One or more therapeutic agents may be encapsulated in the engineered nanovesicles, engineered megakaryocytes, and / or engineered platelets, or supplied together with the engineered nanovesicles, engineered megakaryocytes, and / or engineered platelets in the pharmaceutical composition.Therefore, this article discloses methods for treating, reducing, inhibiting, or preventing cancer in subjects; cancer proliferation; cancer metastasis; and / or treating, reducing, inhibiting, or preventing cancer recurrence, proliferation, or metastasis after surgical resection of a tumor, comprising administering to a subject engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which (or pharmaceutical compositions comprising them) may be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3; and wherein the engineered nanovesicles The vesicles, engineered megakaryocytes, engineered platelets, and / or pharmaceutical compositions further comprise small molecules (including, but not limited to, 1-methyl-tryptophan (1-MT), desmethylhalamine, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vincristine, cyclophosphamide, and 5-fluorouracil), siRNA, peptides, peptide mimics, or antibodies (such as, for example, and anti-PDL-1 antibodies, including, but not limited to, nivolumab, pembrolizumab, abavoxel, BMS-936559, atezolizumab, durvalumab, and avelumab).

[0077] It is understood and anticipated that the chemotherapeutic agents used in the disclosed methods of cancer treatment, inhibition, reduction, and / or prevention may include any chemotherapeutic agents known in the art, including but not limited to abemaciclib, abiraterone acetate, abitrexate (methotrexate), abraxane (paclitaxel albumin-stabilized nanoparticle formulation), ABVD, ABVE, ABVE-PC, AC, AC-T, adcetris (brentuximab vedotin), ADE, ado-trastuzumab emtansine conjugate, doxorubicin (doxorubicin hydrochloride), afatinib dimaleate, afinitor (everolimus), akynzeo (netupitant), and palonosetron hydrochloride. Hydrochloride), Aldara (Imiquimod), Aldesleukin, Alecensa (Alectinib), Allemtuzumab, Alimta (Pemetrexed Disodium), Aliqopa (Copanlisib Hydrochloride), Alkeran (Melphalan Hydrochloride for injection), Alkeran tablets (Melphalan), Aloxi (Palonosetron Hydrochloride), Alunbrig (Brigatinib), Ambochlorin (Chlorambucil), Amboclorin (Chlorambucil), Amifostine, Aminolevulinic acid Acid), Anastrozole, Acrepitant, Aredia (Pamidronate Disodium), Renin (Anastrozole), Anorexin (Exemestane), Arranon (Nelarabine), Arsenic Trioxide, Arzerra (Olfamumab), Asparaginase ErwiniaChrysanthemi), Atezolizumab, Avastin (bevacizumab), Averuzumab, Axitinib, Azacitidine, Bavencio (averuzumab), BEACOPP, Becenum (carmustine), Beleodaq (belindustat), Belindustat, Bendamustine Hydrochloride, BEP, Besponsa (iogamicin), Bevacizumab, Besalotine, Bexxar (tositummomab and iodine I-131 tositummomab), Bicalutamide, BiCNU (carmustine), Bleomycin, Lantumomab, Blincyto (lantumomab), Bortezomib, Bosulif (bosutinib), Bosutinib, Brentuximab Vedotin, Brigatinib, BuMel, Busulfan, Busulfex, Cabozantinib, Cabometyx, Cabozantinib S-Malate, CAF, Calquence (Acalabrutinib), Camptosar (Irinotecan Hydrochloride), Capecitabine (Cap... ecitabine), CAPOX, fluorouracil (Carac) (fluorouracil for external use), carboplatin, carboplatin-paclitaxel, carfilzomib, carmustine (Carmustine), carmustine implants, Casodex (bicalutamide), CEM, ceritinib, daunorubicin (daunorubicin hydrochloride) Hydrochloride, Cervarix (recombinant bivalent HPV vaccine), Cetuximab, CEV, Chloramic acid mustard, Chloramic acid mustard-prednisone, CHOP, Cisplatin, Claribine, Cyclophosphamide, Clofarex, Clolar, CMF, Cobimetinib, Cometriq (cabozotinib malate), CopanlisibHydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen (Dactinomycin D), Cotellic (Cobimetinib), Crizotinib, CVP, Cyclophosphamide, Cyfos (Ifosfamide), Cyramza (Ramucab), Cytarabine, Cytarabine Liposome Liposome, Cytoxan U (cytarabine), Cyclophosphamide, Dabrafenib, Dacarbazine, Dacogen (decitabine), Actinomycin D, Darazalex, Dasatinib, Dazorubicin Hydrochloride, Dazorubicin Hydrochloride and Cytarabine Liposome, Decitabine, Defibrinoside Sodium, Defitelio (defibrinoside Sodium), Degarelix, Denisulin-2, Denosumab, Liposome Cytarabine (Depo) Cyt (cytarabine liposome), dexamethasone, dextromethorphan hydrochloride, dinutuximab, docetaxel, doxil (doxorubicin hydrochloride liposome), doxorubicin hydrochloride, dox-SL (doxorubicin hydrochloride liposome), DTIC-Dome (dacarbazine), durvalumab, fluorouracil (Efudex) (fluorouracil for external use), Elitek (raburicase), epirubicin hydrochloride (Ellence) (epirarubicin hydrochloride) Hydrochloride, elexizumab, oxaliplatin (oxaliplatin), eltrombopag (eltrombopag), enend (aprepitant), empliciti (elexizumab), enasidenib mesylate, enzalutamide, epirubicin hydrochloride, EPOCH, erbitux (cetuximab), erribulin mesylateMesylate), Erivedge (Vismodegib), Erlotinib Hydrochloride, Erwinaze (Erwinia asparaginase), Ethyol (Amifostine), Vanbex (etoposide phosphate), Etoposide, Etoposide phosphate, Doxorubicin Liposome (Doxorubicin Hydrochloride Liposome), Everolimus, Evita (Raloxifene Hydrochloride), Evomela (Melphalan Hydrochloride), Esimerme Tan, 5-FU (fluorouracil injection), 5-FU (fluorouracil - topical), Faretine (toremifene), Farydak (pabistat), Faslodex (fulvestrant), FEC, Flon (letrozole), Figex, Fodora (fludarabine phosphate), Fludarabine phosphate, Fluoroplex (fluorouracil - topical), Fluoroplex injection, Fluoroplex - topical, Flutamide, Foles (methotrexate), Foles PFS (Methotrexate), FOLFIRI, FOLFIRI-Bevacizumab, FOLFIRI-Cetuximab, FOLFIRINOX, FOLFOX, Folotyn (Platratolexa), FU-LV, Fulvestrant, Gardasil (Recombinant HPV Quadrivalent Vaccine), Gardasil 9 (Recombinant HPV 9-valent Vaccine), Gazyva (Atocilizumab), Gefitinib, Gemcitabine Hydrochloride, Gemcitabine-Cisplatin, Gemcitabine-Oxaliplatin, Giemzaptamethasone (Ozomicin), Gemzar (Gemcitabine Hydrochloride), Gilotrif (Afatinib Maleate), Afatinib (Imatinib Mesylate), Gliadel (Carmustine Implant), Gliadel Chip (Carmustine Implant), Guka Pyramidase, Cyclocarpine acetate, Halaven (Eribulin mesylate), Hemangeol (Propranolol hydrochloride), Herceptin (Trastuzumab), Recombinant HPV bivalent vaccine, Recombinant HPV nine-valent vaccine, Recombinant HPV quadrivalent vaccine, Topotecan hydrochloride, Hydroxyurea, Hydroxyurea, Hyper-CVAD, Ibrance (Palbociclib), Imoxicillin, Ibrutinib, ICE, Iclusig (Ponatinib Hydrochloride), IdarubicinHydrochloride, Idarubicin hydrochloride, Idelalisib, Idhifa (ensildenafil mesylate), Ifex (ifosfamide), ifosfamide, pifampin (ifosfamide), IL-2 (aldeleukin), imatinib mesylate, Ibrutinib (Ibruvica), Imfinzi (durvalumab), imiquimod, Imlygic (Talimogene Laherparepvec), Inlyta (axitinib), ozogamicin, recombinant interferon α-2b, interleukin-2 (aldeleukin), intron A (recombinant interferon α-2b), iodine I 131. Tosimomumab and Ipilimumab, Iressa (Gefitinib), Irinotecan Hydrochloride, Irinotecan Hydrochloride Liposome, Istodax (Romidix), Ixapoxone, Ixazomib Citrate, Ixempra (Ixapoxone), Jakafi (Ruxolitinib Phosphate), JEB, Jevtana (Cabbathax), Kadcyla (Trastuzumab-Mestane conjugate), Raloxifene (Keoxifene) (Raloxifene Hydrochloride) Hydrochloride, Keytruda (Pembrolizumab), Kisqali (Ribociclib), Kymriah (Tisagenlecleucel), Kyprolis (Carfilzomib), Lanreotide Acetate, Lapatinib Toluenesulfonate, Lartruvo (Olaratumab), Lenalidomide, Lenvatinib Mesylate Mesylate), Lenvima (lenvatinib mesylate), letrozole, leucovorin calcium, leucoran (chlorambucil), leuprolide acetate, cladribine, levulan (aminolevulinic acid), linfolizin (chlorambucil), LipoDox (doxorubicin hydrochloride liposomes), lomustine, Lonsurf (trifluuridine and tipiracil hydrochloride), leuprolide acetate, leuprolide acetate depot (Lupron Depot), leuprolide acetate suspension.Depot-Ped (Leuprorelin Acetate), Lynparza (Olaparib), Marqibo (Vincristine Sulfate Liposome), Procarbazine Hydrochloride (Matulane), Nitrogen Mustard Hydrochloride, Medroxyprogesterone Acetate, Mekinist (Trametinib), Melphalan, Melphalan Hydrochloride, Mercaptopurine, Mesna, Mesna (Mesna) ), temozolomide (Temozolomide), methotrexate, methotrexate LPF (methotrexate), bromomethyl terbutaline, methotrexate sodium (Mexate) (methotrexate), methotrexate sodium-AQ (methotrexate), midottolin, mitomycin C, mitoxantrone hydrochloride, mitozytrex (mitomycin C), MOPP, Mozobil (prexafo), nitrogen mustard (nitrogen mustard hydrochloride), mitomycin (mitomycin C), busulfan ( Busulfan, Mylosar (azacitidine), Merota (gimenizumab ozomicin), paclitaxel nanoparticles (paclitaxel albumin-stabilized nanoparticle formulation), Noviban (vinorelbine tartrate), Nexilimumab, Nerabin, Cyclophosphamide (Neosar) (Cyclophosphamide), Nerlynx (Neratinib maleate), Netopitant and Palosetron Hydrochloride, Neulasta (pefexazone), Ubuprofen (filgrastim), Sorafenib (Nexavar) Sorafenib tosylate, Nilandron, Nilotinib, Nilotinib, Ninlaro (Ixazomib citrate), Niraparib tosylate monohydrate, Nivolumab, Novadex (Tamoxifen citrate), Nplate (Romilastine), Atorizumab, Odomzo (Sonidegib), OEPA, Ofamumab, OFF, Olaparib, Omacetaxine Mepesuccinate, Oncaspar (Pegaspargase), Ondansetron hydrochloride, Onivyde (Irinotecan hydrochloride liposome), Ontak (Denileukin)Diftitox, Opdivo (nivolumab), OPPA, Osimertinib, Oxaliplatin, Paclitaxel, Paclitaxel albumin-stabilized nanoparticle formulation, PAD, Palbociclib, Palivmin, Palosetron hydrochloride, Palosetron hydrochloride and Nettopitan, Pamidronate disodium, Palimumab, Pabistat, Paraplatin (carboplatin), Pazopanib hydrochloride, PCV, PEB, Pegaspargase, Pegfilgrastim, Peginterferon α-2b Alfa-2b), PEG-intron (pegylated interferon α-2b), pembrolizumab, pemetrexed disodium, Perjeta (pertozumab), cisplatin (Platinol), cisplatin-AQ (cisplatin), prasalifos, pomalidomide, pomalyst (pomalidomide), panatinib hydrochloride, Portrazza (neximetumab), prastrexate, prednisone, procarbazine hydrochloride, aldesleukin (aldesleukin), Prolia (denosumab), Promacta (eltrombopag) Olamine, propranolol hydrochloride, Provenge (Sipuleucel-T), purine (Mercaptopurine), purixan, radium-223 dichloride, raloxifene hydrochloride, ramucirumab, raburicase, R-CHOP, R-CVP, recombinant human papillomavirus (HPV) bivalent vaccine, recombinant human papillomavirus (HPV) nonavalent vaccine, recombinant human papillomavirus (HPV) quadrivalent vaccine Recombinant interferon α-2b, regorafenib, Relistor (methylbromotrione), R-EPOCH, Revlimid (lenalidomide), Methotrexate, Ribociclib, R-ICE, Rituxan, RituxanHycela (rituximab and human hyaluronidase), Rituxan, Rituxan and human hyaluronidase, Rorapitan hydrochloride, Romidixin, Romistachytin, Daunorubicin Hydrochloride, Rubracarib (rucaparib)Camsylate, Ricaprablutracetamol, Ruxotinib Phosphate, Rydapt (Midottolin), Sclerosol Intrapleural Aerosol (Talc), Sesutuximab, Sipuleucel-T, Somadulin Depot (Lanretinib Acetate), Sonidegib, Sorafenib Tosylate, Sprycel (Dasatinib), STANFORD V. Sterile talc, Steritalc, Stivarga (regorafenib), Sunitinib malate, Sunitinib malate, Sylatron (pegylated interferon alpha-2b), Sylvant (staxicumab), Synribo (methotrexate), Tabloid (thioguanine), TAC, Tafinlar (dabrafenib), Tagrisso (osimertinib), Talimogene Laherparepvec, Tamoxifen acetate, Tarabine PFS (cytarabine), Tarceva (erlotinib hydrochloride), Targretin (bexarotin), Tasigna (nilotinib), Taxol (paclitaxel), Taxotere (docetaxel), Tecentriq (atezilumab), Temodar (temozolomide), Temozolomide, Tanciolimus, Thalidomide, Thalidomide, Thioguanine, Thiotepa, Tisagenlecleucel, Tolak (fluorouracil - topical), Topotecan hydrochloride, Toremifene, Torisel (tanciolimus), Tosimomab, and Iodine I 131. Tosimomab, Totect (dextramidine hydrochloride), TPF, Trabectedin, Trametinib, Trastuzumab, Treanda (bendamustine hydrochloride), Trifluuridine and Tipiracil Hydrochloride, Arsenic trioxide (Trisenox) (Arsenic trioxide)Trioxide, Tykerb (lapati dibenzylsulfonate), Unituxin (Dinutuximab), uridine triacetate, VAC, vandetanib, VAMP, Varubi (rorapitan hydrochloride), Vectibix (perumumab), VelP, vincaline sulfate, bortezomib, Velsar (vincaline sulfate), vemurafenib, Venclexta (Venetoclax), Verzenio (abexinib), Viadur (leuprolide acetate), azacitidine (Vidaza), vincaline sulfate, Vincasar PFS (vincaline sulfate injection) Sulfate, vincristine sulfate, vincristine sulfate liposomes, vinorelbine tartrate, VIP, vemodigine, Vistogard (guanosine triacetate), Voraxaze (glutapeptide), vorinsta, Votrient (pazopanib hydrochloride), Vyxeos (daunorubicin hydrochloride and cytarabine liposomes), leucovorin (calcium leucovorin) Calcium), Xalkori (crizotinib), Xeloda (capecitabine), XELIRI, XELOX, Xgeva (denosumab), Xofigo (radium-223 dichloride), Xtandi (enzalutamide), Yervoy (ipilimumab), Yondelis (trabectedine), Zaltrap (aflibercept), Zarxio (filgrastim), Zejula (niraparib tosylate monohydrate), Zelboraf (vemurafenib), Zevalin (teimomab), Zinecard (dexprofen hydrochloride), Ziv-Aflibercept, Zofran (ondansetron hydrochloride), Zoladex (zoledronic acid (Goserelin Acetate)), Zoledronic acid (Zoledronic acid)Acid), Zolinza (volinusta), Zometa (zoledronic acid), Zydelig (edraquinone), Zykadia (cenitinib), and / or Zytiga (abiraterone acetate). Therefore, this document discloses methods for treating, reducing, inhibiting, or preventing cancer in subjects; cancer proliferation; cancer metastasis; and / or treating, reducing, inhibiting, or preventing cancer recurrence, proliferation, or metastasis after surgical resection of a tumor, comprising administering to a subject engineered nanovesicles, engineered megakaryocytes, or engineered platelets encoding one or more exogenous protein receptors, which (or pharmaceutical compositions comprising them) can be used as checkpoint blockers in cancer immunotherapy, wherein the one or more exogenous protein receptors may include PD-1, TIGIT, LAG3, or TIM3; further comprising administering, alone or in the same composition, to the subject any chemotherapeutic agent known in the art, including but not limited to abemaciclib, abiraterone acetate, abitrexate (methotrexate), abraxane (paclitaxel albumin-stabilized nanoparticle formulation), ABVD, ABVE, ABVE-PC, AC, AC-T, and adcetris (Brentuximab). Vedotin), ADE, Ado-Trastuzumab Emtansine, Doxorubicin (Doxorubicin Hydrochloride), Afatinib Dimaleate, Afinitor (Everolimus), Akynzeo (Netupitant and Palonosetron Hydrochloride), Aldara (Imiquimod), Aldesleukin, Alecensa (Alectinib), Allemtuzumab, Alimta (Pemetrexed Disodium), Aliqopa (Copanlisib Hydrochloride), Alkeran (Melphalan Hydrochloride) for injectionHydrochloride), Aloxi (palonosetron hydrochloride), Alunbrig (brigatinib), Ambochlorin (chlorambucil), Amboclorin (chlorambucil), Amifostine, Aminolevulinic Acid, Anastrozole, Acrepitant, Aredia (pamidronate disodium), Reninide (anastrozole), Arranon (nelarabine), Arsenic trioxide, Arzerra (orfamumab), Asparaginase Erwinia chrysanthemi), atezolizumab, Avastin (bevacizumab), averulimumab, axitinib, azacitidine, Bavencio (averulimumab), BEACOPP, Becenum (carmustine), Beleodaq (belindustat), belindustat, bendamustine hydrochloride, BEP, Besponsa (iodizumab / oxamicin), bevacizumab, besalotine, Bexxar (tositummomab and iodine I131 tosimomumab), bicalutamide, BiCNU (carmustine), bleomycin, lantomumab, Blincyto (lantomumab), bortezomib, Bosulif (bosutinib), brentuximabVedotin, Brigatinib, BuMel, Busulfan, Busulfex, Cabozantinib, Cabometyx, Cabozantinib S-Malate, CAF, Calquence (Acalabrutinib), Camptosar (Irinotecan Hydrochloride), Capecitabine (Cap... ecitabine), CAPOX, fluorouracil (Carac) (fluorouracil for external use), carboplatin, carboplatin-paclitaxel, carfilzomib, carmustine (Carmustine), carmustine implants, Casodex (bicalutamide), CEM, ceritinib, daunorubicin (daunorubicin hydrochloride) Hydrochloride, Cervarix (recombinant bivalent HPV vaccine), Cetuximab, CEV, Chloramic acid mustard, Chloramic acid mustard-prednisone, CHOP, Cisplatin, Claribine, Cyclophosphamide, Clofarex, Clolar, CMF, Cobimetinib, Cometriq (cabozotinib malate), CopanlisibHydrochloride, COPDAC, COPP, COPP-ABV, Cosmegen (Dactinomycin D), Cotellic (Cobimetinib), Crizotinib, CVP, Cyclophosphamide, Cyfos (Ifosfamide), Cyramza (Ramucumab), Cytarabine, Cytarabine Liposome, Cedosa-U (Cytarabine), Cytoxan (Cyclophosphamide), Dabrafenib, Dacarbazine, Dacogen (Decitabine), Actinomycin D, Darazalex (Darzalex) Ramumab), Dasatinib, Daunorubicin Hydrochloride, Daunorubicin Hydrochloride and Cytarabine Liposome, Decitabine, Defibrinoside Sodium, Defitelio (Defibrinoside Sodium), Degarelix, Denisil Interleukin-2, Denosumab, Lipocytidine (DepoCyt) (Cytarabine Liposome), Dexamethasone, Dexpromethazine Hydrochloride, Dinutuximab, Docetaxel, Doxil (Doxorubicin Hydrochloride Liposome), Dox-SL (Doxorubicin Hydrochloride Liposome), DTIC-Dome (Dacarbazine), Durvalumab, Efudex (Fluorouracil), Elitek (Raburicase), Ellence (Epirubicin Hydrochloride) (Epirubicin Hydrochloride) Hydrochloride, elexizumab, oxaliplatin (oxaliplatin), eltrombopag (olamine), enmed (aprepitant), empliciti (elexizumab), enasidenib (mesylate), enzalutamide, epirubicin hydrochloride, EPOCH, erbitux (cetuximab), erribulin (eribulin)Mesylate), Erivedge (Vismodegib), Erlotinib Hydrochloride, Erwinaze (Erwinia asparaginase), Ethyol (Amifostine), Vanbex (etoposide phosphate), Etoposide, Etoposide phosphate, Doxorubicin Liposome (Doxorubicin Hydrochloride Liposome), Everolimus, Evita (Raloxifene Hydrochloride), Evomela (Melphalan Hydrochloride), Esimerme Tan, 5-FU (fluorouracil injection), 5-FU (fluorouracil - topical), Faretine (toremifene), Farydak (pabistat), Faslodex (fulvestrant), FEC, Flon (letrozole), Figex, Fodora (fludarabine phosphate), Fludarabine phosphate, Fluoroplex (fluorouracil - topical), Fluoroplex injection, Fluoroplex - topical, Flutamide, Foles (methotrexate), Foles PFS (Methotrexate), FOLFIRI, FOLFIRI-Bevacizumab, FOLFIRI-Cetuximab, FOLFIRINOX, FOLFOX, Folotyn (Platrouxex), FU-LV, Fulvestrant, Gardasil (Recombinant HPV Quadrivalent Vaccine), Gardasil 9 (Recombinant HPV 9-valent Vaccine), Gazyva (Atocilizumab), Gefitinib, Gemcitabine Hydrochloride, Gemcitabine-Ciplatin, Gemcitabine-Oxaliplatin, Giemzaptamethasone (Ozomicin), Gemzar (Gemcitabine Hydrochloride), Gilotrif (Afatinib Maleate), Afatinib (Imatinib Mesylate), Gliadel (Carmustine Implantation) Gliadel chip (carmustine implant), glutamate, silyl acetate, Halaven (eribulin mesylate), Hemangeol (propranolol hydrochloride), Herceptin (trastuzumab), recombinant bivalent HPV vaccine, recombinant nine-valent HPV vaccine, recombinant quadrivalent HPV vaccine, Hemixin (topotecan hydrochloride), hydroxyurea (Hydrea), hydroxyurea, Hyper-CVAD, Ibrance (palbociclib), temomalid, ibrutinib, ICE, lclusig (Ponatinib hydrochloride), edabrine (edabrine hydrochloride)Hydrochloride, Idarubicin hydrochloride, Idelalisib, Idhifa (ensildipine mesylate), Ifex (ifosfamide), ifosfamide, pifampin (ifosfamide), IL-2 (aldeleukin), imatinib mesylate, Ibrutinib (Ibruvica), Imfinzi (durvalumab), imiquimod, Imlygic (Talimogene Laherparepvec), Inlyta (axitinib), ozogamicin, recombinant interferon α-2b, interleukin-2 (aldeleukin), intron A (recombinant interferon α-2b), iodine I 131. Tosimomumab and Ipilimumab, Iressa (Gefitinib), Irinotecan Hydrochloride, Irinotecan Hydrochloride Liposome, Istodax (Romidix), Ixapoxone, Ixazomib Citrate, Ixempra (Ixapoxone), Jakafi (Ruxolitinib Phosphate), JEB, Jevtana (Cabbathax), Kadcyla (Trastuzumab-Mestane conjugate), Raloxifene (Keoxifene) (Raloxifene Hydrochloride) Hydrochloride, Keytruda (Pembrolizumab), Kisqali (Ribociclib), Kymriah (Tisagenlecleucel), Kyprolis (Carfilzomib), Lanreotide Acetate, Lapatinib Toluenesulfonate, Lartruvo (Olaratumab), Lenalidomide, Lenvatinib Mesylate Mesylate), Lenvima (lenvatinib mesylate), letrozole, leucovorin calcium, leucoran (chlorambucil), leuprolide acetate, cladribine, levulan (aminolevulinic acid), linfolizin (chlorambucil), LipoDox (doxorubicin hydrochloride liposomes), lomustine, Lonsurf (trifluuridine and tipiracil hydrochloride), leuprolide acetate, leuprolide acetate depot (Lupron Depot), leuprolide acetate suspension.Depot-Ped (Leuprolide Acetate), Lynparza (Olaparib), Marqibo (Vincristine Sulfate Liposome), Procarbazine Hydrochloride (Matulane) Hydrochloride, nitrogen mustard hydrochloride, megestrol acetate, Mekinist (Trametinib), melphalan, melphalan hydrochloride, mercaptopurine, mesna, mesna (Mesna), temozolomide (Temozolomide), methotrexate, methotrexate LPF, bromomethyl terbutaline, methotrexate sodium (Mexate), methotrexate sodium-AQ (Methotrexate), midotolin, mitomycin C, mitoxantrone hydrochloride, mitozytrex (Mitomycin C), MOPP, Mozobil (Plesafur), nitrogen mustard (nitrogen mustard hydrochloride), mitomycin (Mitomycin C), busulfan (Busulfan), Mylosar (Azacitidine), merota (Gimizumab ozomicin), paclitaxel nanoparticles (paclitaxel white) Protein-stabilized nanoparticle formulations), Noviban (vinorelbine tartrate), Nexilimumab, Nerabin, Cyclophosphamide (Neosar), Neratinib Maleate, Nerlynx (Neratinib Maleate), Netupitan and Palosetron Hydrochloride, Neulasta (pefexastat), Usaprol (filgrastim), Sorafenib Tosylate, Nilandron (nilumet), Nilotinib, Ninlaro (ixazomib citrate), Niraparib Tosylate Monohydrate, Nivolumab, Novadex (tamoxifen citrate), Nplate (romista), Atorizumab, Odomzo (Sonidegib), OEPA, Ofamumab, OFF, Olaparib, Olasumab, Omacetaxine Mepesuccinate), Oncaspar (Pegaspargase), Ondansetron hydrochloride, Onivyde (irinotecan hydrochloride liposome), Ontak (Denileukin)Diftitox, Opdivo (nivolumab), OPPA, Osimertinib, Oxaliplatin, Paclitaxel, Paclitaxel albumin-stabilized nanoparticle formulation, PAD, Palbociclib, Palivmin, Palosetron hydrochloride, Palosetron hydrochloride and Nettopitan, Pamidronate disodium, Palimumab, Pabistat, Paraplatin (carboplatin), Pazopanib hydrochloride, PCV, PEB, Pegaspargase, Pegfilgrastim, Peginterferon α-2b Alfa-2b), PEG-intron (pegylated interferon α-2b), pembrolizumab, pemetrexed disodium, Perjeta (pertozumab), cisplatin (Platinol), cisplatin-AQ (cisplatin), prasalifos, pomalidomide, pomalyst (pomalidomide), panatinib hydrochloride, Portrazza (neximetumab), prastrexate, prednisone, procarbazine hydrochloride, interleukin (Aldesleukin), Prolia (denosumab), Promacta (eltrombopag olamine), propranolol hydrochloride, Provenge (Sipuleucel-T), mercaptopurine ( Purinethol (Mercaptopurine), Purixan (Mercaptopurine), Radium-223 dichloride, Raloxifene hydrochloride, Ramucirumab, Raburicase, R-CHOP, R-CVP, Recombinant Human Papillomavirus (HPV) Bivalent Vaccine, Recombinant Human Papillomavirus (HPV) Nine-valent Vaccine, Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine, Recombinant Interferon Alpha-2b, Regorafenib, Relistor (Methylterebromotrione), R-EPOCH, Revlimid (Lenalidomide), Methotrexate (Rheumatrexate), Ribociclib, R-ICE, Rituxan (Rituximab), Rituxan Hycela (rituximab and human hyaluronidase), rituximab, rituximab and human hyaluronidase, rorapitan hydrochloride, romidixin, romistachytin, daunorubicin (rubidomycin hydrochloride)Hydrochloride), Rubraca (Rucaparib Camsylate), Rucaparib Camsylate, Ruxotinib Phosphate, Rydapt (Midottolin), Sclerosol Intrapleural Aerosol (Talc), Sesuximab, Sipuleucel-T, Somaduline Depot (Lanretinib Acetate), Sonidegib, Sorafenib Tosylate, Sprycel (Dasatinib), STANFORD V. Sterile talc, Steritalc, Stivarga (regorafenib), Sunitinib malate, Sunitinib malate, Sylatron (pegylated interferon alpha-2b), Sylvant (staxicumab), Synribo (methotrexate), Tabloid (thioguanine), TAC, Tafinlar (dabrafenib), Tagrisso (osimertinib), Talimogene Laherparepvec, Tamoxifen acetate, Tarabine PFS (cytarabine), Tarceva (erlotinib hydrochloride), Targretin (bexarotin), Tasigna (nilotinib), Taxol (paclitaxel), Taxotere (docetaxel), Tecentriq (atezilumab), Temodar (temozolomide), Temozolomide, Tanciolimus, Thalidomide, Thalidomide, Thioguanine, Thiotepa, Tisagenlecleucel, Tolak (fluorouracil - topical), Topotecan hydrochloride, Toremifene, Torisel (tanciolimus), Tosimomab, and Iodine I 131. Tosimomab, Totect (dextramidine hydrochloride), TPF, Trabectedin, Trametinib, Trastuzumab, Treanda (bendamustine hydrochloride), Trifluuridine and Tipiracil Hydrochloride, Arsenic trioxide (Trisenox) (Arsenic trioxide)Trioxide, Tykerb (lapati dibenzylsulfonate), Unituxin (Dinutuximab), uridine triacetate, VAC, vandetanib, VAMP, Varubi (rorapitan hydrochloride), Vectibix (perumumab), VelP, vincaline sulfate, bortezomib, Velsar (vincaline sulfate), vemurafenib, Venclexta (Venetoclax), Verzenio (abexinib), Viadur (leuprolide acetate), azacitidine (Vidaza), vincaline sulfate, Vincasar PFS (vincaline sulfate injection) Sulfate, vincristine sulfate, vincristine sulfate liposomes, vinorelbine tartrate, VIP, vemodigine, Vistogard (guanosine triacetate), Voraxaze (glutapeptide), vorinsta, Votrient (pazopanib hydrochloride), Vyxeos (daunorubicin hydrochloride and cytarabine liposomes), leucovorin (calcium leucovorin) Calcium), Xalkori (crizotinib), Xeloda (capecitabine), XELIRI, XELOX, Xgeva (denosumab), Xofigo (radium-223 dichloride), Xtandi (enzalutamide), Yervoy (ipilimumab), Yondelis (trabectedine), Zaltrap (aflibercept), Zarxio (filgrastim), Zejula (niraparib tosylate monohydrate), Zelboraf (vemurafenib), Zevalin (teimomab), Zinecard (dexprofen hydrochloride), Ziv-Aflibercept, Zofran (ondansetron hydrochloride), Zoladex (zoledronic acid (Goserelin Acetate)), Zoledronic acid (Zoledronic acid)Acid), Zolinza (volinusta), Zometa (zoledronic acid), Zydelig (edrabin), Zykadia (ceretinib), and / or Zytiga (abiraterone acetate). The method may also include administration of any therapeutic agent disclosed herein, including but not limited to small molecules (including but not limited to 1-methyl-tryptophan (1-MT), desmethylhalamine, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vincristine, cyclophosphamide, and 5-fluorouracil), siRNA, peptides, peptide mimics, or antibodies (such as, for example, anti-PDL-1 antibodies, including but not limited to nivolumab, pembrolizumab, abavoxelab, BMS-936559, atezolizumab, durvalumab, and avelumab).

[0078] As described above, the disclosed methods may be useful in the treatment of cancer. Representative, but not limited to, the following list of cancers can be treated with the disclosed compositions: lymphoma, B-cell lymphoma, T-cell lymphoma, mycosis fungoides, Hodgkin's disease, myeloid leukemia, bladder cancer, brain cancer, nervous system cancer, head and neck cancer, head and neck squamous cell carcinoma, kidney cancer, lung cancer such as small cell lung cancer and non-small cell lung cancer, neuroblastoma / glioblastoma, ovarian cancer, pancreatic cancer, prostate cancer, skin cancer, liver cancer, melanoma, oral squamous cell carcinoma, pharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, lung squamous cell carcinoma, colon cancer, cervical cancer, breast cancer, and epithelial cancer, kidney cancer, genitourinary cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, hematopoietic cancer, testicular cancer, colorectal cancer, prostate cancer, or pancreatic cancer.

[0079] In one aspect, the disclosed method of treating cancer, including administering to a subject any of the engineered nanovesicles, engineered platelets, or pharmaceutical compositions disclosed herein, may include administering the engineered nanovesicles, engineered platelets, or pharmaceutical compositions at any frequency suitable for treating a specific cancer in the subject. For example, the engineered nanovesicles, engineered platelets, or pharmaceutical compositions may be administered at least every 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, or 48 hours, and every 3, 4, 5, 6, 7, 8, or 9 days. The engineered nanovesicles, engineered platelets, or pharmaceutical compositions are administered to the patient once every 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days, or every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. In one aspect, the engineered nanovesicles, engineered platelets, or pharmaceutical compositions are administered at least once, twice, three times, four times, five times, six times, or seven times per week.

[0080] In one aspect, the amount of engineered nanovesicles, engineered platelets, or pharmaceutical compositions administered to the subject for use in the disclosed methods may include any amount determined by a physician to be suitable for treating a specific cancer of the subject. For example, the amount of the engineered nanovesicles, engineered platelets, or pharmaceutical compositions may be from about 10 mg / kg to about 100 mg / kg. For example, the amount of the engineered nanovesicles, engineered platelets, or pharmaceutical composition applied may be at least 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, 20 mg / kg, 21 mg / kg, 22 mg / kg, 23 mg / kg, 24 mg / kg, 25 mg / kg, 30 mg / kg, 35 mg / kg, 40 mg / kg, 45 mg / kg, 50 mg / kg, 55 mg / kg, 60 mg / kg, 65 mg / kg, 70 mg / kg, 75 mg / kg, 80 mg / kg, 85 mg / kg, 90 mg / kg, 95 mg / kg, or 100 mg / kg. Therefore, in one aspect, this article discloses a method for treating cancer in a subject, wherein the dose of the engineered nanovesicles, engineered platelets, or pharmaceutical composition administered is from about 10 mg / kg to about 100 mg / kg.

[0081] C. Example

[0082] The following examples are provided to provide those skilled in the art with a complete disclosure and description of how to prepare and evaluate the compounds, compositions, articles, apparatus, and / or methods claimed herein, and are intended purely illustrative and not to limit the disclosure. Efforts have been made to ensure the accuracy of figures (e.g., amounts, temperatures, etc.), but some errors and deviations should be accounted for. Unless otherwise stated, parts are parts by weight, temperatures are in °C or at ambient temperature, and pressures are at or near atmospheric pressure.

[0083] 1. Example 1: PD-1 blocking agent vesicles for cancer immunotherapy

[0084] Natural cell membrane-derived vesicles, such as exosomes, microvesicles, and cell membrane repulsion vesicles, hold broad promise for biomedical applications. Similarly, bioengineering strategies are a promising approach for enhancing anti-tumor immunity. Here, cell membrane-derived nanovesicles (NVs) are engineered to display the PD-1 receptor, which enhances cancer immunotherapy by disrupting the PD-1 / PD-L1 immunosuppressive axis (Figure 1A). The PD-1 NVs can bind to the surface of tumor cells and act as PD-L1 blockers (Figures 1A, 1B, and 1C). This blocker is expected to effectively target depleted tumor antigen-specific CD8+. + The NV can also be used to attack tumor cells. Furthermore, it can serve as a carrier for the combined delivery of other therapeutic agents. Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive molecule overexpressed by tumors to limit the proliferation and function of effector T cells. Here, 1-methyl-tryptophan (1-MT), a small molecule inhibitor of IDO, is encapsulated in a PD-1 NV to simultaneously block the PD-1 / PD-L1 axis and overcome the inhibitory effect of tumor-associated IDO on effector T cells within the tumor microenvironment (TME) (Figure 1C).

[0085] To prepare PD-1 Nv, HEK 293T cells stably expressing the mouse PD-1 receptor on the cell membrane were established. The HEK293T cell line is widely used in cell biology research and the biotechnology industry due to its strong transfection ability and ability to produce large amounts of recombinant protein. The DsRed protein tag is contained in the C-terminal portion of the PD-1 receptor protein, which places the protein tag close to the inner lobule of the cell membrane, while the functional domain of the receptor is extracellular (Fig. 1a). Therefore, the mouse PD-1 receptor cDNA was cloned into a mammalian expression vector. HEK 293T cells transfected with hygromycin B were selected to establish a stable cell line. Notably, the PD-1 receptor was primarily expressed and localized on the cell membrane (Fig. 1d). Under the selection pressure of hygromycin B, the cell line continued to express the DsRed PD-1 receptor for more than 20 generations. The cell membrane was labeled with the Alexa-Fluor 488 conjugate wheat germ lectin (WGA) to determine the localization of the PD-1 receptor. As expected, the red fluorescence of the DsRed protein co-localized on the cell membrane with the green fluorescence of the WGA Alexa-Fluor 488 dye (Fig. 1d).

[0086] Next, HEK 293T cells were cultured and lysed, and the cell membranes were isolated. Cell membrane vesicles expressing the PD-1 receptor were prepared by sequential extrusion through polycarbonate membrane filters with pore sizes of 0.8 μm and 0.22 μm. Extrusion through a 0.8 μm polycarbonate membrane filter yielded the major cell membrane vesicles (MVs). Red dots in the confocal image indicate the presence of DsRed-PD-1 on the MVs (Fig. 2a). The size distribution of the MVs was measured by dynamic light scattering (DLS) analysis (Fig. 2b). MVs were then extruded through a 0.22 μm polycarbonate membrane filter. The harvested NVs were further purified by two-step OptiPrep density gradient ultracentrifugation. Next, the morphology of the NVs was characterized by electron microscopy. Negative staining of the NVs by transmission electron microscopy (TEM) showed that they were closed vesicles (Fig. 1e). The NVs were also scanned by cryo-scanning electron microscopy (SEM), showing that they were spherical (Fig. 1f). The electrokinetic potential of the NVs was determined to be -10 mV (Fig. 2c). Furthermore, confocal imaging and Western blotting were used to detect PD-1 receptor expression on NVs. Confocal images showed red dots, indicating the presence of DsRed-PD-1 NVs (Fig. 1g). DLS analysis showed that the average diameter of the NVs was approximately 90–100 nm (Fig. 1h). Additionally, Western blotting analysis showed that the purified NVs contained the PD-1 receptor (Fig. 1i). To verify whether the PD-1 receptor maintained an outward orientation on the NV surface, we performed an immunoprecipitation assay (IP). The assay showed that the PD-1 antibody could pull down most of the PD-1 NVs, indicating that the PD-1 receptor has the correct outward orientation on most PD-1 NVs.

[0087] Cancer cells release antigen-specific CD8+ by overexpressing PD-L1 ligands that interact with the PD-1 receptor. + T cells. To investigate whether PD-1 NV binds to melanoma cells, PD-1 NV was incubated with B16F10 melanoma cells in vitro. DsRed protein fused with the PD-1 receptor produced red fluorescence, which served as a fluorescent marker for PD-1 NV. The cell membrane of B16F10 melanoma cells was stained with WGAAlexa-Fluor 488 dye. Notably, after 2 hours of incubation, PD-1 NV was observed to bind efficiently to the cell membrane surface of B16F10 cells (Fig. 3a). In contrast, Cy5.5-labeled free NV exhibited lower membrane-binding affinity (Fig. 3a). Furthermore, the interaction between PD-1 NV and dendritic cells (DCs) was examined. PD-1 NV was incubated with bone marrow-derived DCs (BMDCs) for 2 hours. Confocal images showed that after 2 hours, DsRed-PD-1 NV effectively bound and was internalized by BMDCs (Fig. 3b). To investigate whether the binding of PD-1 NV to B16F10 cells is mediated through the interaction between PD-1 and PD-L1, the co-localization of the PD-1 receptor on NV and PD-L1 on B16F10 cells was examined for the first time. PD-1 NV was incubated with B16F10 cells expressing EGFP-PD-L1 for 5 h. Notably, PD-1 NV and EGFP-PD-L1 were co-localized on B16F10 melanoma cells (Fig. 3c). To confirm the molecular binding between the PD-1 receptor on NV and PD-L1 on B16F10 cells, an anti-PD-L1 antibody was added to block PD-L1 on B16F10 cells. Confocal images showed that PD-1 NV binding was significantly reduced when cells were pre-incubated with the PD-L1 antibody (aPD-L1). Furthermore, flow cytometry data showed that the number of PD-1 NV cells binding to B16F10 cells was significantly reduced when cells were pre-incubated with the PD-L1 antibody (Fig. 3d). The molecular interaction between the PD-1 receptor and PD-L1 was detected using co-immunoprecipitation (CO-IP). After incubating PD-1 NVs with B16F10 melanoma cells for 20 h, the cells were harvested. The PD-1 receptor on the NVs was pulled down using a primary PD-1 antibody. Notably, the PD-1 antibody pulled down PD-L1 along with the PD-1 receptor (Figure 3e), indicating that the PD-1 NVs physically interact with PD-L1 expressed on B16F10 cells. These results collectively confirm that NVs with PD-1 on their surface can effectively interact with tumor cells through the binding between the PD-1 receptor and PD-L1.

[0088] To investigate the systemic biodistribution and dynamics of PD-1 NV, free NV and PD-1 NV were labeled with Cy5.5. Free NV and PD-1 NV were injected into mice via the tail vein. As shown in Figure 3f, PD-1 NV exhibited higher blood retention compared to free NV. PD-1 NV showed 29% and 13% total retention, respectively, while free NV showed 12% and 1.7% retention at 8 h and 24 h, respectively. Next, the in vivo tissue distribution of PD-1 NV was examined. B16F10 tumor-bearing mice were administered Cy5.5-labeled PD-1 NV via tail vein injection. Notably, Cy5.5 fluorescence of PD-1 NV was observed to accumulate primarily in the liver, kidneys, and tumor sites (Figures 3g and 3h). To further assess the biodistribution of PD-1 NV, confocal imaging was used to quantify the biodistribution of Cy5.5-labeled NV in organ and tumor sections. Cell membranes of tissue sections were stained with WGA Alexa-Fluor 488 dye. The distribution of PD-1 NVs paralleled imaging data showing dense accumulation of PD-1 NVs in tumor tissue sections (Fig. 3i).

[0089] To determine whether PD-1 NV promotes the immune response to melanoma in mice, a melanoma model was established in C57BL / 6 mice subcutaneously inoculated with B16F10-luc cells. Five days after tumor inoculation, mice were injected with 25 mg / kg free NV and 20-30 mg / kg PD-1 NV via tail vein injection. Tumor growth was monitored by measuring bioluminescence signal and tumor size. Notably, B16F10 tumor growth was significantly delayed in mice treated with PD-1 NV at doses of 20 mg / kg, 25 mg / kg, and 30 mg / kg (Figure 4). PD-L1 antibody is a clinically therapeutic antibody that blocks PD-L1 for melanoma treatment. To confirm the in vivo antitumor effect of PD-1 NV, treatment with anti-PD-L1 antibody was used as a positive control. Mice were divided into three groups: those injected with 25 mg / kg free NV (Group 1) and those injected with PD-1 NV (Group 2) via tail vein injection, once every three days for five cycles. Anti-PD-L1 antibody (aPD-L1, group 3) was administered to mice at 2 mg / kg as a positive control. Tumor growth was monitored using bioluminescent signals and tumor size. Notably, PD-1 NV significantly delayed the growth of B16F10 melanoma compared to aPD-L1 treatment (Figs. 5a, 5b, and 5c). Therefore, PD-1 NV improved mouse survival (Fig. 5d), and 20% of mice survived for more than 60 days after PD-1 NV treatment. Furthermore, there was no significant weight loss during treatment (Fig. 5e). No significant antitumor effect was observed in mice treated with free NV.

[0090] Exhausted CD8 + T cells express inhibitory receptor proteins, including PD-1, TIGIT, LAG3, and TIM3, resulting in a reduced ability to produce immune cytokines such as IFN-γ and TNF-α. To assess whether PD-1 NV treatment could reduce T cell depletion and maintain its anti-tumor function, serum IFN-γ and TNF-α levels in treated mice were measured at the end of cycle 5. Serum IFN-γ levels were significantly increased in mice treated with PD-1 NV or aPD-L1 (Figure 5f), while TNF-α levels remained unchanged. CD8+ in harvested tumors was analyzed by flow cytometry. + T cell infiltration. Activated CD8+ cells were observed in tumors collected from mice treated with PD-1 NV or aPD-L1 compared to the control group. + The percentage and number of T cells were significantly increased (Figs. 5g and 5h). Similarly, higher density of CD8 cells was detected in tumors collected from mice treated with PD-1 NV or aPD-L1 by immunofluorescence. + T cells (Figs. 5i and 5j). Finally, the potential toxicity of PD-1 NV was evaluated. After five treatment cycles, blood cell counts (CBCs) showed a slight decrease in lymphocyte and monocyte counts in mice treated with PD-1 NV, while the lymphocyte ratio remained unaffected. Furthermore, plasma levels of immunoglobulin E (IgE) antibodies, generated by the immune system in response to an overreaction to allergens, did not significantly increase after five cycles of PD-1 NV treatment.

[0091] Next, the IDO inhibitor 1-MT was loaded into PD-1 NVs to investigate the combination therapy of the IDO inhibitor and the immune checkpoint blocker. The electroporation method achieved a higher 1-MT loading efficiency (24.5%) compared to the conventional incubation method (16.5%). The release of 1-MT from PD-1 NVs was also tested. 1-MT was rapidly released from NVs in vitro within 24 hours. Furthermore, to determine the inhibitory effect of 1-MT-loaded PD-1 NVs on 1-MT release, IDO inhibition assays were performed on IDO-expressing HeLa cells stimulated with IFN-γ. Notably, PD-1-loaded 1-MT exhibited better inhibitory effects compared to free 1-MT and free NVs loaded with 1-MT. Figure 6 To evaluate drug release within the tumor, the accumulation of PD-1 NV within the tumor was measured. Cy5.5-labeled PD-1 NV accumulated in the tumor within 30 minutes after injection, and the accumulation gradually increased over time, indicating that 1-MT can be effectively released into the tumor. Figure 7 ).

[0092] To demonstrate that PD-1 NV loaded with 1-MT simultaneously provides enhanced antitumor activity through IDO inhibition and PD-L1 blockade, B16F10-luc tumor-bearing mice were treated with PBS (Group 1), free NV (Group 2), free 1-MT (Group 3), PD-1 NV (Group 4), free NV loaded with 1-MT (Group 5), 1-MT plus αPD-L1 (Group 6), or PD-1 NV loaded with 1-MT (Group 7), once every 3 days for a total of five cycles. Tumor growth was monitored by measuring bioluminescent signals and tumor size. In mice treated with free 1-MT and free NV loaded with 1-MT (60%), a high response rate (>80%) was observed, but limited inhibition of tumor growth was noted (Figs. 8a and 8b). This less-than-ideal efficacy may be due to multiple immunosuppressive mechanisms present in the tumor microenvironment (TME). Notably, PD-1 NV exhibited better antitumor activity compared to 1-MT (Figs. 8a and 8b). Mice treated with 1-MT plus aPD-L1 showed a significant delay in melanoma tumor progression (Figs. 8a and 8b). Importantly, treatment with 1-MT-loaded PD-1 NV showed a response rate greater than 80% against melanoma, which was more effective than treatment with 1-MT or PD-1 NV alone (Figs. 8a and 8b) and comparable to treatment with 1-MT plus aPD-L1 (Figs. 8a and 8b). Furthermore, the dual inhibition of IDO and PD-L1 by 1-MT-loaded PD-1 NV improved survival in treated mice without significant weight loss (Fig. 8c). CD8+ was detected at the tumor margin in different treatment groups. + T cell density. Tumor-infiltrating CD8 cells were harvested from all treatment groups. + T cells were analyzed by flow cytometry and immunofluorescence. Results showed that NV treatment with free 1-MT and 1-MT-loaded T cells reduced infiltrated CD8 cells compared to the PBS treatment group. + T cell numbers increased by approximately 15-20% (Figures 8d and 8e). Immunofluorescence staining confirmed that PD-1 and PD-1 NVs loaded with 1-MT significantly enhanced tumor infiltration CD8. + T density (Figure 8f). Combination therapy was more effective than monotherapy. CD4 was also investigated. + FoxP3 + T cell infiltration was observed. Notably, compared to the control group, the PD-1 NV group loaded with 1-MT showed increased CD4 counts. + FoxP3 +T cell reduction. Finally, major organs such as the liver, spleen, kidney, heart, and lungs were collected and evaluated using immunohistochemistry; no obvious signs of organ damage were observed. These data indicate that IDO inhibition combined with the PD-L1 blocker PD-1 NV can significantly disrupt the immunosuppression of the TME and enhance the host immune system's clearance of cancer cells.

[0093] In summary, cellular nanocarriers displaying the PD-1 receptor are designed to effectively bind PD-L1 on tumor cells and disrupt the PD-1 / PD-L1 inhibitory axis. PD-L1 blockers using PD-1 NVs significantly enhance the in vivo immune response against melanoma tumors. Furthermore, PD-1 NVs can be used to carry multiple therapeutic agents for synergistic efficacy. PD-1 NVs loaded with 1-MT achieve both IDO inhibition and PD-L1 blockade. Simultaneous disruption of the tumor's dual immune tolerance mechanism significantly inhibits in vivo melanoma growth. Therefore, PD-L1 blockers using PD-1 cellular NVs offer a promising strategy that leverages the functions of delivery carriers and drug encapsulation to enhance immunotherapy.

[0094] a) Methods and Materials

[0095] (1) Chemicals and reagents:

[0096] 1-MT, hygromycin B, a mixture of phosphatase inhibitors, and Optiprep solution were ordered from Sigma-Aldrich. mGMSF, mIL-4, and mTNF-α were ordered from Thermo Fisher Scientific. PD-L1 antibody was from Thermo Scientific. Anti-PD-1 antibody for Western blotting was from Sigma-Aldrich. Mouse CD4 and CD8 antibodies for immunofluorescence staining were ordered from Abcam. Anti-PD-L1 antibody (aPD-L1) for in vivo use was purchased from Biolegend. Protein A / G agarose beads were purchased from Santa Cruz. Wheat germ lectin (WGA), Alexa Fluor 488, and 594 dyes were purchased from Thermo Scientific. Staining antibodies for CD3, CD4, and CD8 used in FACS analysis were ordered from Biolegend.

[0097] (2) Plasmids and cell lines:

[0098] Mouse PD-1 was cloned into the pCMV6 mammalian expression vector. The plasmid was confirmed by automated DNA sequencing. The mouse EGFP-PD-L1 plasmid was purchased from Sinocare Biotechnology Co., Ltd. HEK293T cells were transiently transfected with the plasmid using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. To establish stable cells, HEK293T cells were transfected with pCMV6-OFR-PD-1 and further selected with hygromycin B. The results were obtained using Lipofectamine. TM The transfection reagent (Invitrogen, 18324012) was used to transfect B16F10 cells with the EGFP-PD-L1 plasmid.

[0099] (3) Cell culture:

[0100] HEK293T cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The mouse melanoma cell line B16F10 was purchased from the American Type Culture Collection. For in vivo bioluminescent tumor imaging, B16F10-luc cells were a gift from Dr. Ye Huang of UNC. HeLa cells were obtained from the Tissue Culture Facility of UNC Lineberger Comprehensive Cancer Center. Bone marrow-derived dendritic cells (DCs) were obtained by culturing cells isolated from the bone marrow of C57BL / 6 mice in RPMI 1640 supplemented with 10% FBS, 20 ng mGM-CSF, and 10 ng IL-4.

[0101] (4) Preparation of cell membrane nanovesicles:

[0102] HEK293T cells stably expressing DsRed-PD-1 were cultured in DMEM medium containing 10% FBS. Cells were harvested with trypsin. After centrifugation at 1000 rpm, the cells were washed three times with cold PBS. Then, the cells were resuspended in homogenized medium (HM) containing 0.25 M sucrose, 1 mM EDTA, 20 mM Hepes-NaOH (pH 7.4), and a mixture of protease inhibitors. The cells were then homogenized at least 50 times on ice using a Dunns homogenizer. The entire solution was rotated at 1000 × g for 5 min. The precipitate was then discarded, and the supernatant was centrifuged at 100,000 × g for 1 h. The precipitate containing plasma membrane material was washed three times with HM buffer. To prepare cell membrane nanovesicles, the cell membranes in HM buffer were passed through a 0.8 μm filter at least 10 times, and then through a 0.22 μm filter 10 times. To further purify the nanovesicles, the extruded sample was subjected to a step gradient of 50% iodixanol (Optiprep) and then ultracentrifuged at 100,000×g for 2 h at 4 °C.

[0103] (5) Isolation of DC cells from mouse bone marrow:

[0104] Bone marrow-derived dendritic cells (DCs) were isolated from the bone marrow. In summary, femurs and tibias were isolated from C57BL / 6 mice and placed on ice in RPMI 1640 medium. The ends of each bone were severed with scissors, and the bone marrow was flushed with 2 mL of RPMI 1640 medium using a syringe. Large particles of the cell-containing medium were removed by passing it through a Nytex mesh. The cells were centrifuged at 1000 rpm for 5 minutes, and the supernatant was discarded. The cells were resuspended in erythrocyte lysis buffer (Thermo Scientific) and lysed for 5 minutes at room temperature. The bone marrow cells were washed twice with RPMI 1640, centrifuged at 1000 rpm for 10 minutes each time at room temperature. Cells were seeded in culture dishes containing RPMI 1640 medium, with the addition of mouse granulocyte / macrophage colony-stimulating factor (mGM-CSF, 50 ng / mL) and IL-4 (10 ng / mL). Cell aggregates were observed between days 5 and 8. The aggregates were removed and the cells were gently dispersed in RPMI 1640 medium. The cells were then seeded in 6-well plates containing RPMI 1640 supplemented with mGM-CSF, 50 ng / mL and IL-4 for further use.

[0105] (6) 1-MT load:

[0106] To load 1-MT into PD-1 NV, 1 mg of purified vesicles and 500 μg of 1-MT (100 mg / mL diluted in PBS at pH 10) were gently mixed in 1 mL of electroporation buffer (1.15 mM potassium phosphate, pH 7.2, 25 mM potassium chloride, 21% Optiprep) at 4 °C. The sample was electroporated at 300 V and 150 μF in a 0.4 cm electroporation cup using a micropulse electroporator (Bio-Rad, USA). The electroporation cup containing the sample was then incubated on ice for 30 min for membrane recovery. The NV was then washed three times with cold PBS by ultracentrifugation at 100,000 × g. For an alternative method of loading 1-MT into nanovesicles, 1 mg of purified vesicles and 500 μg of 1-MT were gently mixed in 1 mL of PBS and incubated at 37 °C for 2 h. The nanovesicles were then washed three times with PBS.

[0107] (7) Protein blotting:

[0108] Immunoblot analysis was performed. Briefly, HEK293T cells stably expressing DsRed-PD1 were lysed using RIPA lysis buffer (Thermo Scientific). Cell lysates and purified membrane vesicle samples were then separated by 12% SDS-PAGE, and immunoblotting analysis was performed using PD-1 and β-actin antibodies, followed by enhanced chemiluminescence (ECL) detection (Thermo Scientific).

[0109] (8) CO-IP determination:

[0110] To detect the interaction between PD-1 on nanovesicles (NVs) and PD-L1 on B16F10 cells, a Co-IP assay was performed. Simply put, 1 mL (700 μg / mL) of PD-1 NV was added and incubated with B16F10 cells (10 cm culture dish) for 20 h. Cells were then washed three times with PBS to remove unbound NVs. Cells were then lysed in 1 mL of RIPA lysis buffer (Thermo Scientific) containing a mixture of phosphatase inhibitors. Cell lysis was clarified by centrifugation at 15000 × g for 10 min at 4 °C. The clarified lysate was pre-removed by gently rotating it with protein G-agarose beads (Santa Cruz) at 4 °C for 1 h. The cell lysate was then incubated overnight with PD-1 primary antibody at 4 °C with shaking. The next day, the cells were incubated with 10 μL of protein G-agarose beads at 4 °C for 2 h. The beads were then gently washed five times with ice-cold RIPA buffer. The binding proteins were separated using 12% SDS-PAGE, and immunoblotting analysis was performed using the antibodies shown.

[0111] (9) Immunoprecipitation assay (IP assay):

[0112] Immunoprecipitation (IP) assay was performed to detect PD-1 receptor orientation. Simply put, 1 mL (500 μg / mL) of PD-1 NV was pre-incubated with protein A / G beads at room temperature for 1 h to remove non-specific binding proteins. Then, PD-1 NV was incubated with 2 μg of PD-1 primary antibody at 4 °C for 5 h. Afterward, 10 μL of protein A / G agarose beads were added, and the mixture was incubated at room temperature for 2 h. The beads were gently washed three times with PBS. Binding proteins were separated using 12% SDS-PAGE, and immunoblotting analysis was performed using the indicated antibodies.

[0113] (10) Nanovesicle cell binding assay:

[0114] B16F10 cells were seeded in confocal culture dishes. DsRed-PD-1 NVs (50 μg / mL) or free PD-1 NVs labeled Cy5.5 (50 μg / mL) were added to the culture medium as indicated and incubated for 20 h. aPD-L1 antibody (20 μg / mL) was incubated with the cells for 4 h, and then the PD-1 NVs were added to the culture medium. Wheat germ lectin (WGA) and Alexa Fluor 488 conjugate were then added to the cell membrane for 10 min. BMDCs (7 days after bone marrow isolation) were seeded in confocal wells, and 10 U TNF-α was added to stimulate DC maturation. DsRed-PD-1 NV (50 μg / mL) was then added and incubated with the DCs for 20 h. Wheat germ lectin (WGA) and Alexa Fluor 488 conjugate were then added to the cell membrane for 10 min. The nuclei were then stained with Hoechst for 10 min. The cells were washed three times with PBS. Confocal microscopy was performed using a 63× objective in sequential scanning mode on a Zeiss microscope. For flow cytometry analysis of PD-1 NV binding to B16F10 cells, PD-1 NV (50 μg / mL) was incubated with B16F10 cells for 2 h as shown. Alternatively, cells were incubated with aPD-L1 antibody (20 μg / mL) for 4 h, followed by addition of PD-1 NV to the culture medium. Gated to DsRed + .

[0115] (11) Drug release:

[0116] The release of 1-MT from NV (1 mg / mL) was analyzed in PBS (pH 7.2) at 37 °C. The amount of 1-MT released was determined by HPLC. Separation was performed in a gradient of acetonitrile-increasing sodium acetate buffer (50 mM, pH 4.2) at a flow rate of 1.0 mL / min. The absorbance of the column effluent was monitored at 280 nm.

[0117] (12) Cellular assay of IDO activity:

[0118] To detect the inhibitory effect of 1-MT on IDO, for the IDO enzyme activity assay, HeLa human tumor cells were seeded at 4.0 × 10⁴ cells / well in DMEM / phenol red-free medium supplemented with 80 μM L-tryptophan, 10% FBS (Hyclone), and penicillin-streptomycin (Gibco). The next day, 1-MT or 1-MT@PD-1 NV was dissolved in DMSO / 0.1N HCl and serially diluted in the assay wells, maintaining a DMSO / HCl dilution constant of 1:1000. Then, 100 ng / mL of recombinant human IFN-γ (catalog number #570206, BioLegend Inc. San Diego, Ca) was added to each well to stimulate IDO expression. Tryptophan was identified by fluorescence detection at an excitation wavelength of 285 nm and an emission wavelength of 365 nm, or by HPLC at 280 nm.

[0119] (13) Loop

[0120] Free NV and PD-1 NV were labeled with NHS-Cy5.5 in PBS buffer. After incubation overnight at 4°C, the Cy5.5-labeled PD-1 NV was washed three times with PBS. 200 μL (2 mg / mL) of Cy5.5-labeled free NV and PD-1 NV were injected into C57BL / 6 mice via tail vein. Blood samples were collected from the orbital sinus at different time points after injection (2 min, 2 h, 4 h, 8 h, 24 h, and 48 h). Serum fluorescence signals were then measured.

[0121] (14) Biodistribution:

[0122] PD-1 NV was labeled with NHS-Cy5.5 in PBS buffer. After incubation overnight at 4°C, the Cy5.5-labeled PD-1 NV was washed three times with PBS. 200 μL (2 mg / mL) of Cy5.5-labeled PD-1 NV was injected into melanoma-bearing C57BL / 6 mice via tail vein. The control group was injected with PBS. Major organs and tumors were harvested from the mice at 24 h and 48 h. Finally, fluorescence imaging and mean fluorescence intensity were recorded using the Xenogen IVIS spectral imaging system.

[0123] (15) In vivo anti-tumor efficacy study:

[0124] Female C57BL / 6 mice were purchased from the Jackson Laboratory in the United States. All mouse studies were conducted in accordance with animal protocols approved by the Institutional Animal Care and Use Committee of North Carolina State University and the University of North Carolina at Chapel Hill. Mice were weighed and randomly assigned to different groups. The peritoneal tumors of mice reached 40-50 mm in volume. 3 ) Subcutaneous transplantation 1×10 6 Five days after B16F10 tumor cells were introduced, mice were administered PBS, free nanovesicles (25 mg / kg), PD-1 nanovesicles (25 mg / kg), 1-MT (2.5 mg / kg), PD-1 nanovesicles loaded with 1-MT (25 mg / kg), and anti-PD-L1 antibody (2 mg / kg) via tail vein injection. Tumor incidence was monitored by physical examination, and size was measured over time using digital calipers. Tumor volume (V) was calculated as V = d 2 ×D / 2, where d is the shortest tumor diameter and D is the longest tumor diameter, in mm. To assess potential toxicity, daily weight loss in mice was monitored. Survival assays were performed separately.

[0125] (16) In vivo bioluminescence and imaging:

[0126] Bioluminescence images were acquired using the Xenogen IVIS spectral imaging system. Data were acquired using in vivo imaging software (Xenogen) 10 minutes after intraperitoneal injection of d-fluorescein (Pierce) in DPBS (15 mg / mL).

[0127] (17) Tissue immunofluorescence assay:

[0128] Tumors were dissected from mice and flash-frozen in optimal cutting medium (OCT). Several micron-sized sections were cut using a cryostat and mounted on slides. Frozen organ (lung, liver, heart, kidney, spleen) and tumor sections were incubated in PBS for 15 minutes to remove the embedding medium. Samples were blocked for 30 minutes with buffer containing 3% BSA and 0.5% Triton X-100. For organs, samples were incubated with WGA Alexa Fluor 488 for 10 minutes. For tumor samples, tumor sections were then incubated overnight with CD4 and CD8 primary antibodies (1:50 in 1.5% BSA), followed by washing three times with PBS for 5 minutes each time. They were then incubated in the dark at room temperature for 1 hour with TRITC secondary antibody (KPL) diluted in 1.5% BSA. Finally, cell nuclei were stained with DAPI, and the tissues were washed three times with PBS for 5 minutes each time. Confocal microscopy was performed in continuous scanning mode using a 40x objective lens on a FLUO-VIEW laser scanning confocal microscope (Zeiss).

[0129] (18) Cytokine detection:

[0130] Plasma samples were isolated from mice after various treatments and diluted for analysis. Tumor necrosis factor (TNF-α, Invitrogen) and interferon-γ (IFN-γ, eBioscience) were analyzed using ELISA kits according to the manufacturer's protocol.

[0131] (19) Hematoxylin-eosin staining:

[0132] Major organs (liver, spleen, kidney, heart, and lung) from mice that received different treatments were collected and fixed in 10% neutral buffered formalin. The organs were then routinely processed into paraffin, cut into 8 μm sections, stained with hematoxylin and eosin, and finally examined under a digital microscope.

[0133] (20) Statistical analysis:

[0134] As shown in the figures, all results are expressed as mean ± standard deviation, or mean ± standard error. Biological parallel assays were used in all experiments unless otherwise specified. When comparing more than two groups as indicated (multiple comparisons), one-way or two-way ANOVA and Tukey's post-hoc test were used. The log-rank test was used to determine survival benefit. All statistical analyses were performed using IBM SPSS Statistical 19. The threshold for statistical significance was P < 0.05.

[0135] 2. Example 2: PD-1-expressing platelets for cancer immunotherapy

[0136] Currently, besides PD-L1, many intrinsic and extrinsic mechanisms exist that contribute to resistance to immunotherapy, including tumor antigen expression, CTLA-4 and other immune checkpoints, and the loss of immunosuppressive cell populations (Tregs, MDSCs, type II macrophages). Among these immunoblockers, CD4... + CD25 + FoxP3 + Regulatory T cells (T cells) reg Cells compete for IL-2 depletion in the tumor microenvironment, which inhibits the infiltration of CD8+ cells in tumors. + T cell proliferation. In addition, activated T cells... reg Cells can also directly kill T cells through perforin. Therefore, a large number of T cells are present in tumor tissue. reg Cells are a key obstacle to successful cancer immunotherapy. reg Cell depletion significantly increased the response rate to PD-1 / PD-L1 blockade.

[0137] Platelets have recently been used to design nanocarriers, serving as a monitor for vascular injury, invasive microorganisms in the bloodstream, and circulating tumor cells (CTCs). Platelets conjugated to anti-PD-L1 can target tumor surgical wounds, activating depleted CD8+ cells. + T cell reactivation reduces postoperative tumor recurrence and metastasis. However, blood-derived platelets present biosafety and insufficiency challenges due to the need for large quantities of host-matched platelets during treatment. Furthermore, platelets are anucleate and cannot proliferate or be genetically manipulated. Alternatively, in vitro production from megakaryocytes (MKs) can provide a large-scale platelet source. In this study, megakaryocytes were genetically engineered to stably express mouse PD-1, and PD-1-presenting platelets were subsequently generated in vitro. Platelets were then processed by restoring depleted CD8+. + T cell reactivation to apply these cells to surgical wounds (Figure 9A) Figure 6 B and Figure 9C In addition to PD-L1 blockers, PD-1-expressing platelets can also carry and transport cyclophosphamide, which allows for the depletion of Tregs within the tumor microenvironment and further enhances CD8+ in the surgical tumor microenvironment. + The anti-tumor effect of T lymphocytes.

[0138] In addition to blocking PD-L1, PD-1 platelets can also act as a platform and bind with other immunosuppressive inhibitors to enhance response rates. Therefore, cyclophosphamide was co-loaded into platelets to deplete Treg cells. The cyclophosphamide-loaded PD-1 platelet formulation disrupted the immunosuppression of both PD-L1 and Treg cells, significantly increasing the number of revitalized CD8+ cells in the surgical tumor microenvironment. + Ki67+ GrzmB + The frequency of lymphocytes. Therefore, PD-1 platelets, as a cellular platform, can be combined with other immune-blocking inhibitors to improve response rates and reduce postoperative tumor recurrence rates.

[0139] (1) Generation of MK cell lines stably expressing PD-1

[0140] Platelets are released from bone marrow and lung-resident MK cells. To produce platelets on a large scale, mouse MK progenitor cells L8057 were treated with phorbol 12-myristate 13-acetate (PMA). Upon stimulation, cell volume increased significantly, accompanied by proplatelet expansion and platelet release. MK cells with larger cell volumes contained multiple nuclei, indicating maturity and readiness to release platelets. To produce PD-1 platelets, a stable L8057 cell line expressing mouse EGFP-PD-1 was established by transduction with lentivirus and post-selection with puromycin. Notably, the PD-1 receptor was expressed and localized on the cell membrane, indicated by fluorescence from EGFP and co-localization of the cell membrane dye Alexa Fluor 594 conjugate wheat germ lectin (WGA594) (Fig. 10A). PD-1 expression on EGFP-PD-1 L8057 cells was confirmed by Western blotting (Fig. 10B). The MK marker CD41a was concentratedly expressed in the PD-1 L8057 cell line. Upon stimulation with PMA, PD-1-expressing L8057 cells underwent maturation, exhibiting a typical peripheral nucleus and increased cytoplasmic volume. The MK maturation marker CD42a was expressed on the cell membrane (Fig. 10C). Furthermore, platelet surface receptor GPVI (collagen receptor) and P-selectin were expressed in mature PD-1 L8057 cells. Wright-Giemsa staining revealed that mature PD-1 L8057 cells contained polyploid nuclei (Fig. 10D).

[0141] (2) In vitro production of PD-1 platelets from MK

[0142] Mature proplatelets typically reside in budding pseudopodia in the bone marrow and lungs, elongating to form platelets. Proplatelets traverse the sinusoidal endothelium and release platelets into the bloodstream. Similarly, mature PD-1-expressing L8057 cells possess budding pseudopodia that elongate to form proplatelets (Fig. 10E). Notably, proplatelets bud and extend from the cell membrane to form pearl-like structures (Fig. 10F). Proplatelets eventually disintegrate and release platelets. (EGFP-PD-1-containing cells are also mentioned.) +The MK cytoplasm of membrane vesicles serves as a membrane reservoir for proplatelet formation (Fig. 10F). These PD-1-expressing membrane vesicles fuse to form tubular structures and bud from the cell surface (Fig. 10F). Purified platelets from the culture medium showed green fluorescence, indicating the presence of PD-1 in the platelets (Fig. 10G). Binding receptors, including GPVI and P-selectin, were also expressed in platelets released from L8057 cells. Furthermore, DLS analysis showed that the platelets had a mean diameter of approximately 2 μm and an electrokinetic potential of -10 ± 2.6 mV (Fig. 10H). As demonstrated by cryo-scanning electron microscopy (CSEM) and transmission electron microscopy (TEM), the purified platelets exhibited a spherical morphology (Fig. 10I and Fig. 10J). In addition, platelet production from PD-1 L8057 cells was quantitatively measured, and platelet production significantly increased on day 6 after PMA stimulation (Fig. 10I and Fig. 10J). Figure 10K ).

[0143] (3) Biological behavior of PD-1 platelets

[0144] Platelets contribute to hemostasis, recruit other leukocytes for host defense responses, and release several immunologically active molecules. Platelet activation occurs after adhesion to vascular lesions. Collagen is the primary subendothelial component bound by active platelets. Therefore, the collagen-binding properties of PD-1 platelets were tested. Indeed, free and PD-1 platelets labeled with WGA Alexa-Fluor 594 dye exhibited strong collagen adhesion (Figs. 11a and 11b). In contrast, blocking the collagen receptor GPVI with anti-GPVI antibody strongly reduced the collagen adhesion of platelets. Thrombosis via platelet aggregation is another key event in the hemostatic response. In response to thrombin agonist stimulation, free and PD-1 platelets efficiently aggregate among themselves. Furthermore, platelet microparticles (PMPs) are generated from activated platelets carrying chemokines and adhesion molecules, thereby promoting monocytes in sites of inflammation and atherosclerosis. To examine whether PMP could be generated from activated PD-1 platelets upon stimulation, platelets were treated with thrombin in vitro. CLSM, SEM, and TEM images showed that PMP was generated from activated platelets (Fig. 11c). It was also observed that the platelet morphology became more dendritic and swollen after thrombin treatment (Fig. 11c). Furthermore, DLS analysis detected the generation of smaller particles, indicating the release of PMP from activated platelets (Fig. 11d).

[0145] Increased expression of PD-L1 on tumor cells leads to T cell depletion (T exTo investigate whether PD-1 platelets could bind to the surface of melanoma cancer cells and block PD-L1, PD-1 platelets were incubated in vitro with B16F10 melanoma cancer cells. Notably, PD-1 platelets effectively bound to B16F10 cells and were subsequently internalized by the cancer cells (Fig. 11e). In contrast, free platelets showed limited binding capacity to B16F10 cells (Fig. 11e). To examine whether the PD-L1 / PD-1 interaction mediates platelet internalization, an anti-PD-L1 antibody was added to block PD-L1 on B16F10 cells. Confocal images showed a significant reduction in PD-1 platelet binding when cells were pre-incubated with the PD-L1 antibody. Furthermore, EGFP-PD-1 platelets co-localized with PD-L1 ligands on B16F10 melanoma cells, indicating an interaction between PD-1 and PD-L1 (Fig. 11f). To investigate the systemic circulation time of free and PD-1 platelets, platelets were labeled with Cy5.5 and subsequently injected into mice via tail vein. Free platelets exhibited a slightly longer blood retention time (14%, 24 hours) compared to PD-1 platelets (8%, 24 hours) (Fig. 11g). Both free and PD-1 platelets accumulated in the residual tumor bed when intravenously inoculated with Cy5.5-labeled platelets after tumor resection in B16F10 tumor-bearing mice (Fig. 11H and 11Q). Figure 11I Meanwhile, platelets accumulate in the liver and spleen (Figure 11H and 11H). Figure 11I Glycoprotein VI (GPVI) is a collagen receptor on platelets and is responsible for directing platelets to wounds. PD-1 platelets and free platelets exhibit similar collagen-binding abilities (Figure 11A). Therefore, the accumulation capacity in surgical tumors is similar between free platelets and PD-1 platelets (Figure 11H).

[0146] (4) In vivo antitumor effect of PD-1 platelets

[0147] Upregulation of PD-L1 on melanoma cells leads to T cell depletion, resulting in dysfunction in T cell proliferation and activity. To investigate whether PD-1 platelets can block PD-L1 to induce residual tumor regression after surgery, a B16F10 melanoma incomplete tumor resection model was used to simulate postoperative local recurrence (Figure 12a). When the tumor volume grew to 100 mm... 3 At approximately 10:00 AM, mice were intravenously injected with a single dose of phosphate-buffered saline (PBS) and free platelets (1 × 10⁻⁶). 8 PD-1 platelets (1×10) 8Immediately after platelet injection, mice underwent tumor surgery to remove most of the tumor (approximately 90%). Following surgery, mice received additional treatment during wound healing (Fig. 12a). Notably, a high response rate was achieved in mice receiving PD-1 platelets, as assessed by monitoring tumor bioluminescence and measuring tumor size (Fig. 12b and Fig. 12c). In mice receiving PD-1 platelets, progression of residual tumors was significantly delayed by monitoring the bioluminescence signal of B16F10 cells and measuring tumor size (Fig. 12b and Fig. 12c). In contrast, residual melanoma tumors developed rapidly in mice receiving free platelets or PBS (Fig. 12b and Fig. 12c). Thanks to PD-1 platelet treatment, 25% of mice survived for more than 60 days without significant weight loss or other signs of toxicity (Fig. 12d). No obvious signs of organ damage were observed in platelet-treated mice. To examine CD8... + TIL accumulation was observed, and tumors were collected and analyzed using fluorescence-activated cell sorting (FACS) and immunofluorescence. Notably, CD8+ was observed in the tumors of mice treated with PD-1 platelets. + The frequency of TILs was significantly increased (Fig. 12E, Fig. 12F, and Fig. 12G), and T cells exhibited increased expression of the cytotoxic protein granzyme B (GzmB), suggesting that PD-1-expressing platelets were able to restore T cell depletion within the tumor microenvironment (Fig. 12H and). Figure 12I ).

[0148] (5) In vivo antitumor effect of PD-1 platelets loaded with cyclophosphamide

[0149] Low doses of cyclophosphamide can improve immune responses in various mouse tumor models and patients, which is generally attributed to selective depletion of Tregs. To counteract Tregs at tumor sites, we loaded cyclophosphamide into platelets. Platelets were found to internalize and release cyclophosphamide in vitro within 24 hours. To investigate the simultaneous antitumor effect of PD-L1 blockade and cyclophosphamide-induced Treg depletion, the same B16F10 melanoma model with incomplete tumor resection was used. In this model, while cyclophosphamide and PD-1-expressing platelets showed limited results when used as single agents (Fig. 13A and Fig. 14A), tumor progression was significantly inhibited in mice treated with PD-1-expressing platelets loaded with cyclophosphamide (P < 0.001) (Fig. 13A and Fig. 14A). Treg depletion induced by simultaneous cyclophosphamide and PD-L1 blockade improved survival in treated mice (Fig. 13B).

[0150] The study also investigated CD4 levels in tumors after treatment. + Treg and CD8 +The frequency of TILs. Free cyclophosphamide and platelets loaded with cyclophosphamide selectively depleted intratumoral Tregs (Fig. 13C and Fig. 14B) and increased Ki67. + The frequency of T cells (Fig. 13D, Fig. 13E). Notably, although platelets expressing PD-1 have a limited effect in reducing Tregs, they still increase Ki67. + The frequency of T cells (Fig. 13D, Fig. 13E). Notably, in tumors collected from mice treated with PD-1-expressing platelets loaded with cyclophosphamide, CD8... + The frequency of TILs was significantly increased (Fig. 13F, Fig. 13G), and these cells showed GzmB expression (Fig. 13H, Fig. 13I). Immunofluorescence staining also showed that, compared with control mice, infiltrating CD8 cells were significantly increased in mice treated with PD-1-expressing platelets loaded with cyclophosphamide. + Increased T cell density (Figure 13J) Figure 13K Mice treated with low-dose cyclophosphamide and cyclophosphamide-loaded platelets showed delayed abdominal hair growth and slight weight loss (Fig. 14A). Figure 14C These results indicate that the combination of PD-1-expressing platelets and cyclophosphamide effectively disrupts the immune blockade against PD-L1 and depletes Tregs, thereby leading to a reduced postoperative tumor recurrence rate.

[0151] b) Conclusion

[0152] In summary, PD-1-containing platelets are genetically engineered to accumulate at surgical wound sites and block PD-L1 on residual tumor cells, thereby depleting CD8+. + T cells strongly recover, thereby eliminating residual tumor cells. Megakaryotic progenitor cells were engineered to express mouse Pd-1, and induced to produce PD-1-presenting platelets. In addition to blocking PD-L1, PD-1 platelets can also act as a platform and bind to other immunosuppressive inhibitors to enhance response rates. A PD-1 platelet formulation loaded with cyclophosphamide disrupted the immunosuppression of PD-L1 and Treg cells, significantly increasing the number of revitalized CD8+ cells in the surgical tumor microenvironment. + Ki67 + GrzmB + Lymphocyte frequency. Revitalized CD8 cells. + Eliminate residual tumor cells and reduce the postoperative tumor recurrence rate.

[0153] c) Method

[0154] (1) Chemicals and reagents

[0155] Cyclophosphamide, thrombin, Wright-Giemsa solution, and a mixture of phosphatase inhibitors were ordered from Sigma-Aldrich. The PD-1 antibody was from Thermo Scientific. The PD-L1 antibody was from Sigma-Aldrich. Mouse CD41a (ab63983) and CD42a (ab173503) antibodies were from Abcam. P-selectin (sc-8419) was from Santa Cruz Biotechnology. The mouse GPVI (MAB6758) antibody was from R&D Systems. Mouse CD4 and CD8 antibodies for immunofluorescence were purchased from Abcam. Staining antibodies including CD3, CD4, CD8, Ki67, and Foxp3 for FACS analysis were ordered from Biolegend. Wheat germ agglutinin (WGA), Alexa Fluor 488, and 594 dyes were ordered from Thermo Scientific.

[0156] (2) Cell Culture

[0157] HEK293T cells were cultured in Dulbecco modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS). The mouse megakaryocyte line L8057 was provided by Professor Alan Cantor of Boston Children's Hospital and Dana-Farber Cancer Institute and cultured in RPMI 1640 containing 20% ​​FBS. The mouse melanoma cell line B16F10 was purchased from the American Type Culture Collection. For bioluminescent in vivo tumor imaging, B16F10-luc cells were a gift from Dr. Ye Huang of UNC. B16F10 cells were cultured in DMEM supplemented with 10% FBS.

[0158] (3) Plasmids and stable cell lines

[0159] Lenti vector (pLenti-C-mGFP-PD-1-puro) containing a C-terminal monomeric GFP tag for mouse PD-1 and the Lenti-vpak packaging kit containing the packaging plasmid and transfection reagent were purchased from Origene. HEK293T cells were transiently transfected with the plasmid using the transfection reagent from the lenti-vpak packaging kit, according to the manufacturer's instructions. L8057 cells were infected with the lenti-virus packaged from HEK293T cells and incubated with 6 μg / ml polybrene. 96 h after infection, L8057 cells were cultured in RPMI-1640 with 20% FBS supplemented with 1 μg / ml puromycin to screen for cell lines stably expressing mouse PD-1. The established L8057 cells stably expressing mouse EGFP-PD-1 were then preserved in 20% FBS supplemented with 0.5–1 μg / ml puromycin.

[0160] (4) Platelet preparation from L8057 cells

[0161] L8057 cells and PD-1L8057 cells were cultured in RPMI 1640 with 20% FBS. For maturation and differentiation, L8057 cells were stimulated with 100–500 nM PMA for 3 days. Cells were then cultured for more than 6 days to produce proplatelet and platelet cells. To isolate platelets, the culture medium was centrifuged at 1500 rpm for 20 minutes to remove cells. The supernatant was then centrifuged at 12,000 rpm for 20 minutes at room temperature. The platelet pellet was carefully resuspended in Delross buffer (134 mM NaCl, 12 mM NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM HEPES, pH 7.4) or PBS with 1 μM PGE1. For viable platelets, 0.5 U thrombin was added to the platelet suspension. -1 PGE1 is removed before platelet activation.

[0162] (5)Wright-Giemsa staining

[0163] L8057 cells were stimulated with 100-500 nM PMA for 3 days. Cells were then harvested and washed three times with PBS buffer. Cells were then fixed with anhydrous methanol for 5 minutes. Cells were stained with Wright-Giemsa staining solution for 5 minutes. The stained cells were then washed three times with PBS buffer. Finally, the stained cells were observed under a microscope with a 40× objective lens.

[0164] (6) Cell immunofluorescence assay

[0165] L8057 cells stably expressing EGFP-PD-1 were washed three times with PBS. The cells were then fixed with 4% paraformaldehyde for 10 minutes. After washing twice with PBS, the cells were incubated with 0.2% Triton X-100 for 5 minutes. The cells were then blocked with buffer containing 3% BSA for 1 hour. L8057 cells were then incubated overnight at 4°C with CD41a, CD42a, and p-selectin primary antibodies, respectively. The cells were washed three times with PBS. The cells were then incubated for 1 hour at room temperature in the dark with rhodamine-conjugated secondary antibody (KPL) diluted in 1.5% BSA. Finally, the cell nuclei were stained with DAPI for 10 minutes. The cells were then washed three times with PBS for 5 minutes each time. The cells were examined by confocal microscopy in sequential scanning mode using a 63× objective lens on a FLUO-VIEW laser scanning confocal microscope (Zeiss).

[0166] (7) Protein blotting

[0167] Immunoblot analysis was performed. Briefly, L8057 cells and L8057 cells stably expressing EGFP-PD1 were lysed using RIPA lysis buffer (Thermo Scientific). Cell lysates were then separated using 12% SDS-PAGE and analyzed using immunoblotting antibodies against PD-1, CD41a, CD42a, p-selectin, GPVI, and β-actin, followed by enhanced chemiluminescence (ECL) detection (Thermo Scientific).

[0168] (8) B16F10 cell binding assay

[0169] B16F10 cells were seeded in confocal wells. Platelets expressing EGFP-PD-1 (~0.5 × 10⁻⁶) were then seeded. 8 Or free platelets labeled with cy5.5 (~0.5×10⁻⁶) 8 The culture medium was added and incubated with B16F10 cells overnight. Then, wheat germ lectin (WGA) and Alexa Fluor 594 conjugate were added to stain the B16F10 cell membranes for 10 minutes. Next, the cell nuclei were stained with Hoechst for 10 minutes. The cells were washed three times with PBS. Confocal microscopy was performed in sequential scanning mode using a 63× objective lens on a Zeiss confocal microscope.

[0170] (9) Collagen binding assay

[0171] Type I / III collagen derived from mice (Bio-Rad) was reconstituted to a concentration of 2.0 mg / mL in 0.25% acetic acid. 200 μL of collagen solution was then added to each well of a 96-well assay plate and incubated overnight at 4°C. Prior to collagen binding studies, the plates were blocked with 2% BSA and washed three times with PBS. For collagen binding studies, platelets were stained with WGA Alexa Fluor 594 for 30 min and then washed three times with PBS. Labeled platelets (~1 × 10⁻⁶) were added. 7 Reproduce collagen-coated or non-collagen-coated plates. After incubation for 30 seconds, wash the plates three times. Then dissolve the retained nanoparticles with 100 μl DMSO and perform fluorescence quantification using a Tecan Infinite M200 reader.

[0172] For confocal imaging, a collagen solution was added to the confocal well and incubated overnight at 4°C. (~1×10⁻⁶) 8The wells were sealed with 2% BSA, and the WGA Alexa Fluor 594-labeled platelets were incubated with collagen for 2 minutes, followed by washing three times with PBS. The platelets were examined under a confocal microscope (Zeiss) in sequential scanning mode with a 63× objective.

[0173] (10) Aggregation determination

[0174] Platelet aggregation was assessed spectrophotometrically. Platelets in PBS were loaded into cuvettes. 0.5 IU of platelets was added as shown. -1 Thrombin (Sigma Aldrich) was added to the platelets. The cuvettes were immediately placed in a Tecan Infinite M200 reader, and absorbance at 650 nm was monitored over time. For confocal imaging, the platelets were labeled with WGA Alexa Fluor 594. The platelets were then loaded into the confocal wells, and 0.5 IU was added. -1 Thrombin was collected for 30 minutes. The sample was examined under a confocal microscope (Zeiss) in sequential scanning mode using a 63× objective.

[0175] (11) Drug loading and release

[0176] To load cyclophosphamide onto platelets, 100 μg of purified platelets (~1×10⁻⁶) were used. 8 100 μg of cyclophosphamide was gently mixed with 1 ml of PBS and incubated at 37 °C for 2 h. The platelets were then washed three times with PBS by centrifugation at 12,000 rpm. For electroporation shock, 100 μg of purified platelets (approximately 1 × 10⁻⁶) were added to PBS at room temperature. 8 100 μg of cyclophosphamide was gently mixed with 1 mL of electroporation buffer (1.15 mM potassium phosphate, pH 7.2, 25 mM potassium chloride, 21% Optiprep). The sample was electroporated at 300 V and 150 μF in a 0.4 cm electroporation cup using a micropulse electroporator (Bio-Rad, USA). The electroporation cup containing the sample was then incubated for 30 min for membrane recovery. Platelets were then washed three times with PBS at 1,2000 rpm. Cyclophosphamide release from platelets (100 μg / mL) at different time points (1 h, 2 h, 4 h, 8 h, 24 h, and 48 h) at 37 °C was analyzed in PBS (pH 7.2). The amount of cyclophosphamide released was analyzed using a UV-Vis spectrophotometer at a maximum k-value of 202 nm.

[0177] (12) Loop

[0178] PD-1 platelets and free platelets produced from L8057 cells were labeled with NHS-Cy5.5. The platelets were then washed three times with PBS. 200 μL of labeled free platelets (approximately 2 × 10⁻⁶) were injected into C57BL / 6 mice via the tail vein. 8 ) or PD-1 platelets (~2×10) 8 Blood samples were collected from the eye sockets of mice at different time points after injection (2 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 24 hours, and 48 hours). Serum fluorescence was then measured.

[0179] (13) Biodistribution

[0180] Free platelets and PD-1-containing platelets produced by L8057 cells were labeled with NHS-Cy5.5 in PBS buffer. After incubation overnight at 4°C, the Cy5.5-labeled platelets were washed three times with PBS. 200 μL of Cy5.5-labeled PD-1 platelets (approximately 2 × 10⁻⁶) were injected via tail vein into melanoma-bearing C57BL / 6 mice. 8 The control group was injected with PBS. After 24 hours, the mice were sacrificed, and cancerous cells and major organs were harvested. Finally, fluorescence imaging results and average radio intensity were recorded using the Xenogen IVIS spectral imaging system.

[0181] (14) Study on in vivo anti-tumor efficacy.

[0182] B16F10 luciferase-labeled B16F10 (1×10⁻⁶) 6 Melanoma cells were transplanted into the right side of C57BL / 6 mice. Eight days after tumor inoculation, the tumor volume reached approximately 150 mm. 3 Then these tumors were removed, leaving approximately 15mm. 3 (10%) of the tumor volume was used to simulate residual tumor on the operating table. Simply put, animals were anesthetized in an induction chamber with isoflurane (up to 5% for induction; 1-3% for maintenance), and anesthesia was maintained via a nasal cone. The tumor area was excised and aseptically prepared. Approximately 90% of the tumor was removed using sterile instruments. The wound was closed using an automated wound closure system. Mice were randomly divided into several groups of eight (n=8) as shown. Mice were first intravenously injected with different therapeutic agents: PBS, free platelets (~2×10⁻⁶). 8 PD-1 platelets (~2×10) 8 ), cyclophosphamide (20 mg / kg), and free platelets loaded with cyclophosphamide (~2 × 10⁻⁶). 8 ) or PD-1 platelets loaded with cyclophosphamide (~2×10) 8Immediately after injection, mice were operated on one after another within 10 minutes. Tumor burden was monitored by bioluminescence of cancer cells. Mice were trimmed and shaved with depilatory cream prior to imaging. Images were captured using the IVIS Lumina imaging system (Perkin Elmer). Tumor size was measured using digital calipers. (Major axis × Minor axis) 2 ) / 2 to calculate tumor volume (mm) 3 When signs of health impairment appear or the tumor size exceeds 2cm. 3 At that time, the animals were euthanized.

[0183] (15) Tissue immunofluorescence assay.

[0184] Tumors were dissected from mice and flash-frozen in optimal cutting medium (OCT). Several micron-sized sections were cut using a cryostat and mounted on glass slides. Frozen tumor sections were incubated in PBS for 15 minutes to remove the embedding medium. Specimens were blocked with buffer containing 3% BSA. Subsequently, specimens were incubated overnight with CD4 and CD8 primary antibodies (1:50 in 3% BSA), followed by washing three times with PBS for 5 minutes each time. Specimens were then incubated for 1 hour at room temperature in the dark with TRITC secondary antibody (KPL) diluted in 3% BSA. Finally, cell nuclei were stained with DAPI, and tissues were washed three times with PBS for 5 minutes each time. Confocal microscopy was performed using a 40x objective lens on a FLUO-VIEW laser scanning confocal microscope (Zeiss) in continuous scanning mode.

[0185] (16) Statistical analysis.

[0186] As shown in the figures, all results are expressed as mean ± standard deviation, or mean ± standard error. Biological parallel assays were used in all experiments unless otherwise specified. When comparing more than two groups (multiple comparisons), one-way or two-way ANOVA and Tukey post-hoc tests were used. Survival benefits were determined by the log-rank test. All statistical analyses were performed using IBM SPSS Statistical 19. The threshold for statistical significance was P < 0.05.

[0187] D. References

[0188] ADFesnak,CHJune,BLLevine,Nat.Rev.Cancer 2016,16,566-581.

[0189] A.Hoos,Nat.Rev.Drug.Discov.2016,15,235-247.

[0190] A.K.Palucka,L.M.Coussens,Cell 2016,164,1233-1247

[0191] Alvarez-Erviti,L.et al.Delivery of siRNA to the mouse brain bysystemic injection of targeted exosomes.Nature biotechnology 29,341-345,doi:10.1038 / nbt.1807(2011).

[0192] Amezquita,R.A.&Kaech,S.M.Immunology:The chronicles of T-cellexhaustion.Nature 543,190-191,doi:10.1038 / nature21508(2017).

[0193] Anselmo,A.C.et al.Platelet-like nanoparticles:mimicking shape,flexibility,and surface biology of platelets to target vascular injuries.ACSnano 8,11243-11253,doi:10.1021 / nn503732m(2014).

[0194] B.T.Luk,L.Zhang,J.Control Release 2015,220,600-607

[0195] Balachandran,V.P.et al.Identification of unique neoantigen qualitiesin long-term survivors of pancreatic cancer.Nature 551,512-516,doi:10.1038 / nature24462(2017).

[0196] Berd,D.&Mastrangelo,M.J.Effect of low dose cyclophosphamide on theimmune system of cancer patients:depletion of CD4+,2H4+suppressor-inducer T-cells.Cancer research 48,1671-1675(1988).

[0197] Boussiotis,V.A.Molecular and Biochemical Aspects of the PD-1Checkpoint Pathway.The New England journal of medicine 375,1767-1778,doi:10.1056 / NEJMra1514296(2016).

[0198] C.M.Hu,L.Zhang,S.Aryal,C.Cheung,R.H.Fang,Proc.Natl.Acad.Sci.U.S.A.2011,108,10980-10985

[0199] C.M.Hu,R.H.Fang,K.C.Wang,B.T.Luk,S.Thamphiwatana,D.Dehaini,P.Nguyen,P.Angsantikul,C.H.Wen,A.V.Kroll,C.Carpenter,M.Ramesh,V.Qu,S.H.Patel,J.Zhu,W.Shi,F.M.Hofman,T.C.Chen,W.Gao,K.Zhang,S.Chien,L.Zhang,Nature 2015,526,118-121

[0200] C.Robert,A.Ribas,JDWolchok,FSHodi,O.Hamid,R.Kefford,JSWeber,AMJoshua,WJHwu,TCGangadhar,A.Patnaik,R.Dronca,H.Zarour,RWJoseph h,P.Boasberg,B.Chmielowski,C.Mateus,MAPostow,K.Gergich,J.Elassaiss-Schaap,XNLi,R.Iannone,SWEbbinghaus,SPKang,A.Daud,Lancet 2014,384,1109-1117

[0201] J.Robert,GVLong,B.Brady,C.Dutriaux,M.Maio,L.Mortier,JCHassel,P.Rutkowski,J.McNeil,E.Kalinka-Warzocha,KJSavage,MMHernberg,C.Lebbe,J.Charles,C.Michalcioiu,V.Chiarion. ileni,J.Mauch,F.Cognetti,A.Arance,H.Schmidt,D.Schadendorf,H.Gogas,L.Lundgren-Eriksson,J.Horak,B.Sharkey,IMWaxman,V.Atkinson,PAAscierto,N.Engl.J.Med.2013,3033.

[0202] J.Robert,J.Schachter,GVLong,A.Arance,JJGrob,L.Mortier,A.Daud,MSCarlino,C.McNeil,M.Lotem,J.Larkin,P.Lorigan,B.Naynes,CU Blank,O.Hamid,J.Mateus,R.Shapira-Frommer,M.Kosh,H.Zhou,N.Ibrahim,S.Ebbinghaus,A.Ribas,N.Engl.J.Med.2015,372,2521-2532

[0203] C.Wang,W.Sun,Y.Ye,Q.Hu,H.N.Bomba,Z.Gu,Nat.Biomed.Eng.2017,1,0011

[0204] C.Wang,Y.Ye,Q.Hu,A.Bellotti,Z.Gu,Adv.Mater.2017,29。

[0205] D.H.Munn,A.L.Mellor,J.Clin.Invest.2007,117,1147-1154.

[0206] Disis,M.L.&Stanton,S.E.Can immunity to breast cancer eliminateresidual micrometastases?Clinical cancer research:an official journal of theAmerican Association for Cancer Research 19,6398-6403,doi:10.1158 / 1078-0432.CCR-13-0734(2013).

[0207] E.J.Wherry,Nat.Immunol.2011,12,492-499.

[0208] E.J.Wherry,S.J.Ha,S.M.Kaech,W.N.Haining,S.Sarkar,V.Kalia,S.Subramaniam,J.N.Blattman,D.L.Barber,R.Ahmed,Immunity 2007,27,670-684.

[0209] El-Andaloussi,S.et al.Exosome-mediated delivery of siRNA in vitro andin vivo.Nature protocols 7,2112-2126,doi:10.1038 / nprot.2012.131(2012).

[0210] G.Frumento,R.Rotondo,M.Tonetti,G.Damonte,U.Benatti,G.B.Ferrara,J.Exp.Med.2002,196,459-468.

[0211] G.M.Lynn,R.Laga,P.A.Darrah,A.S.Ishizuka,A.J.Balaci,A.E.Dulcey,M.Pechar,R.Pola,M.Y.Gerner,A.Yamamoto,C.R.Buechler,K.M.Quinn,M.G.Smelkinson,O.Vanek,R.Cawood,T.Hills,O.Vasalatiy,K.Kastenmuller,J.R.Francica,L.Stutts,J.K.Tom,K.A.Ryu,A.P.Esser-Kahn,T.Etrych,K.D.Fisher,L.W.Seymour,R.A.Seder,Nat.Biotechnol.2015,33,1201-1210

[0212] Grossman,W.J.et al.Human T regulatory cells can use the perforinpathway to cause autologous target cell death.Immunity 21,589-601,doi:10.1016 / j.immuni.2004.09.002(2004).

[0213] Gubin,M.M.et al.Checkpoint blockade cancer immunotherapy targetstumor-specific mutant antigens.Nature 515,577-581,doi:10.1038 / nature13988(2014).

[0214] Gulfam,M.et al.Anticancer drug-loaded gliadin nanoparticles induceapoptosis in breast cancer cells.Langmuir:the ACS journal of surfaces andcolloids 28,8216-8223,doi:10.1021 / la300691n(2012).

[0215] H.Liu,K.D.Moynihan,Y.Zheng,G.L.Szeto,A.V.Li,B.Huang,D.S.Van Egeren,C.Park,D.J.Irvine,Nature 2014,507,519-522

[0216] H.Zhou,Z.Fan,P.K.Lemons,H.Cheng,Theranostics 2016,6,1012-1022.

[0217] Hoos,A.Development of immuno-oncology drugs-from CTLA4 to PD1 to thenext generations.Nature reviews.Drug discovery 15,235-247,doi:10.1038 / nrd.2015.35(2016).

[0218] Hu,C.M.et al.Nanoparticle biointerfacing by platelet membranecloaking.Nature 526,118-121,doi:10.1038 / nature15373(2015).

[0219] Hu,Q.et al.Anticancer Platelet-Mimicking Nanovehicles.Adv Mater 27,7043-7050,doi:10.1002 / adma.201503323(2015).

[0220] Huang,A.C.et al.T-cell invigoration to tumor burden ratio associatedwith anti-PD-1 response.Nature 545,60-65,doi:10.1038 / nature22079(2017).

[0221] I.Mellman,G.Coukos,G.Dranoff,Nature 2011,480,480-489

[0222] J.Kim,WALi,Y.Choi,SALewin,CSVerbeke,GDranoff,DJMooney,Nat.Biotechnol.2015,33,64-72

[0223] J. Park, SHWrzesinski, E. Stern, M. Look, J. Criscione, R. Ragheb, SMJay, SLDement, A. Agawu, PLLimon, Nat.Mater.2012,11,895-905

[0224] JRBrahmer, SSTykodi, LQChow, WJHwu, SLTopalian, Hwu P, CGDrake, LHCamacho, Kauh J, Odunsi K, HPitot, Hamid O, Bhatia S, Martins R, Eaton K, Che n,TMSalay,S.Alaparthy,JFGrosso,AJKorman,SMParker,S.Agrawal,SMGoldberg,DMPardoll,A.Gupta,JMWigginton,N.Engl.J.Med.2012,366,2455-2465

[0225] Jang,SCet al.Bioinspired exosome-mimetic nanovesicles for targeted delivery of chemotherapeutics to malignant tumors.ACS Nano 7,7698-7710,doi:10.1021 / nn402232g(2013).

[0226] Matsunaga K, Saitoh K, Tabata H, Omori T, Satoh T, Kurotori N, Maejima I, Shirahama-Noda K, Ichimura Isobe T, Akira S, Noda T, Yoshimori T, Nat.CellBiol.2009,11,385-396.

[0227] Kensler,TT,Behme,RJ&Brooke,D.High-performance liquidchromatographic analysis of cyclophosphamide.Journal of pharmaceuticalsciences 68,172-174(1979).

[0228] L.Alvarez-Erviti,Y.Seow,H.Yin,J.Betts,S.Lakhal,MJWood,NatBiotechnol 2011,29,341-345;

[0229] LCWu,AAZarrin,Nat.Rev.Immunol.2014,14,247-259.

[0230] L.Gu,DJMooney,Nat.Rev.Cancer 2016,16,56-66

[0231] L.Jeanbarth,MASwartz,Proc.Natl.Acad.Sci.USA2015,112,14467-14472

[0232] LMKranz,M.Dicken,H.Haas,S.Kreiter,J.Loquai,KCReuter,M.Meng,D.Fritz,F.Vascotto,H.Hefesha,J.Grunwitz,M.Vormehr,Y.Husemann,A.Selmi,ANKuh n,J.Buck,E.Derhovanesian,R.Rae,S.Attig,J.Diekmann,RAJabulowsky,S.Heesch,J.Hassel,P.Langguth,S.Grabbe,C.Huber,O.Tureci,U.Sahin,Nature 2016,534,396-401:

[0233] L.Riechmann,M.Clark,H.Waldmann,G.Winter,Nature 1988,332,323-327

[0234] Lefrancais,E.et al.The lung is a site of platelet biogenesis and areservoir for haematopoietic progenitors.Nature 544,105-109,doi:10.1038 / nature21706(2017).

[0235] M.S.Goldberg,Cell 2015,161,201-204

[0236] M.T.Stephan,J.J.Moon,S.H.Um,A.Bershteyn,D.J.Irvine,Nat.Med.2010,16,1035-1041;

[0237] M.Xie,H.Ye,H.Wang,G.Charpin-El Hamri,C.Lormeau,P.Saxena,J.Stelling,M.Fussenegger,Science 2016,354,1296-1301;

[0238] Machlus,K.R.&Italiano,J.E.,Jr.The incredible journey:Frommegakaryocyte development to platelet formation.The Journal of cell biology201,785-796,doi:10.1083 / jcb.201304054(2013).

[0239] Maj,T.et al.Oxidative stress controls regulatory T cell apoptosis andsuppressor activity and PD-L1-blockade resistance in tumor.Nature immunology18,1332-1341,doi:10.1038 / ni.3868(2017).

[0240] Mause,S.F.,von Hundelshausen,P.,Zernecke,A.,Koenen,R.R.&Weber,C.Platelet microparticles:a transcellular delivery system for RANTESpromoting monocyte recruitment on endothelium.Arteriosclerosis,thrombosis,andvascular biology 25,1512-1518,doi:10.1161 / 01.ATV.0000170133.43608.37(2005).

[0241] Moreau,T.et al.Large-scale production of megakaryocytes from humanpluripotent stem cells by chemically defined forward programming.Naturecommunications 7,11208,doi:10.1038 / ncomms11208(2016).

[0242] O.Hamid,C.Robert,A.Daud,F.S.Hodi,W.J.Hwu,R.Kefford,J.D.Wolchok,P.Hersey,R.W.Joseph,J.S.Weber,R.Dronca,T.C.Gangadhar,A.Patnaik,H.Zarour,A.M.Joshua,K.Gergich,J.Elassaiss-Schaap,A.Algazi,C.Mateus,P.Boasberg,P.C.Tumeh,B.Chmielowski,S.W.Ebbinghaus,X.N.Li,S.P.Kang,A.Ribas,N.Engl.J.Med.2013,369,134-144

[0243] Ott,P.A.et al.An immunogenic personal neoantigen vaccine for patientswith melanoma.Nature 547,217-221,doi:10.1038 / nature22991(2017).

[0244] PC Tumeh, C.L. Harview, J.H. Earley, I.P.S. Shintaku, E.J. Taylor, L. Robert, B. Chmielowski, M. Spasic, G. Henry, V. Ciobanu, A.N.West, M. Carmona, C. Kivork, E. Seja, G. Cherry, A.J. Gutierrez, T.R.Grogan, C. Mateus, G. Tomasic, J.A.Glaspy, R.O. Emerson, H. Robins, R.H. Pierce, D.A. Elashoff, C. Robert, A. Ribas, Nature 2014, 515, 568-571

[0245] P.Sharma,JPAllison,Cell 2015,161,205-214

[0246] P.Sharma,JPAllison,Science 2015,348,56-61

[0247] P.Vader,EAMol,G.Pasterkamp,RMSchiffelers,Adv.Drug.Deliv.Rev.2016,106,148-156

[0248] P.Zhang,Y.Chen,Y.Zeng,C.Shen,R.Li,Z.Guo,S.Li,Q.Zheng,C.Chu,Z.Wang,Z.Zheng,R.Tian,S.Ge,X.Zhang,NSXia,G.Liu,X.Chen,Proc.Natl.Acad.Sci.USA2015,112,E6129-6138.

[0249] Q.Hu,W.Sun,C.Qian,C.Wang,HNBomba,Z.Gu,Adv.Mater.2015,27,7043-7050.

[0250] RHFang,CMHu,BTLuk,W.Gao,JACopp,Y.Tai,DEO'Connor,L.Zhang,Nano Lett.2014,14,2181-2188;

[0251] R.Kuai,LJOchyl,KSBahjat,A.Schwendeman,JJMoon,Nat.Mater.2016.

[0252] R.van der Meel,MHFens,P.Vader,WWvan Solinge,O.Eniola-Adefeso,RMSchiffelers,J.Control Release 2014,195,72-85

[0253] Rollinghoff,M.,Starzinski-Powitz,A.,Pfizenmaier,K.&Wagner,H.Cyclophosphamide-sensitive T lymphocytes suppress the in vivo generation of antigen-specific cytotoxic T lymphocytes.The Journal of experimental medicine145,455-459(1977).

[0254] Ruggeri,ZM&Mendolicchio,GLAdhesion mechanisms in platelet function.Circulation research 100,1673-1685,doi:10.1161 / 01.RES.0000267878.97021.ab(2007).

[0255] SBStephan,AMTaber,I.Jileaeva,EPPegues,CLSentman,MTStephan,Nat.Biotechnol.2015,33,97-101

[0256] SCJang,OYKim,CMYoon,DSChoi,TYRoh,J.Park,J.Nilsson,J.Lotvall,YKKim,YSGho,ACS Nano 2013,7,7698-7710.

[0257] S.El-Andaloussi,Y.Lee,S.Lakhal-Littleton,J.Li,Y.Seow,C.Gardiner,L.Alvarez-Erviti,ILSargent,MJWood,Nat.Protoc.2012,7,2112-2126;

[0258] SKSchmidt,S.Siepmann,K.Kuhlmann,HEMeyer,S.Metzger,S.Pudelko,M.Leineweber,W.Daubener,PLoS One 2012,7,e44797.

[0259] SLTopalian,JMTaube,RAAnders,DMPardoll,Nat.Rev.Cancer 2016,16,275-287

[0260] SSTaneja,J.Urol.2012,188,2148-2149

[0261] SSTaneja,J.Urol.2012,188,2149.

[0262] STKoshy,DJMooney,Curr.Opin.Biotechnol.2016,40,1-8

[0263] S. Tan, T. Wu, D. Zhang, Z. Zhang, Theranostics 2015, 5, 863-881

[0264] Schumacher,TN&Schreiber,RDNeoantigens in cancer immunotherapy.Science 348,69-74,doi:10.1126 / science.aaa4971(2015).

[0265] Semple, JW, Italiano, JE, Jr. & Freedman, J. Platelets and the immune continuum.

[0266] Sharma,P.&Allison,J.P.Immune checkpoint targeting in cancer therapy:toward combination strategies with curative potential.Cell 161,205-214,doi:10.1016 / j.cell.2015.03.030(2015).

[0267] Sharma,P.&Allison,J.P.The future of immune checkpoint therapy.Science348,56-61,doi:10.1126 / science.aaa8172(2015).

[0268] Sharma,P.,Hu-Lieskovan,S.,Wargo,J.A.&Ribas,A.Primary,Adaptive,andAcquired Resistance to Cancer Immunotherapy.Cell 168,707-723,doi:10.1016 / j.cell.2017.01.017(2017).

[0269] Siljander,P.R.Platelet-derived microparticles-an updatedperspective.Thrombosis research 127 Suppl 2,S30-33,doi:10.1016 / S0049-3848(10)70152-3(2011).

[0270] Stephan,S.B.et al.Biopolymer implants enhance the efficacy ofadoptive T-cell therapy.Nature biotechnology 33,97-101,doi:10.1038 / nbt.3104(2015).

[0271] Stroncek,D.F.&Rebulla,P.Platelet transfusions.Lancet 370,427-438,doi:10.1016 / S0140-6736(07)61198-2(2007).

[0272] T.R.Fadel,F.A.Sharp,N.Vudattu,R.Ragheb,J.Garyu,D.Kim,E.P.Hong,N.Li,G.L.Haller,L.D.Pfefferle,S.Justesen,K.C.Herold,T.M.Fahmy,Nat.Nanotechnol.2014,9,723-723

[0273] Tian,Y.et al.A doxorubicin delivery platform using engineered naturalmembrane vesicle exosomes for targeted tumor therapy.Biomaterials 35,2383-2390,doi:10.1016 / j.biomaterials.2013.11.083(2014).

[0274] Tohme,S.,Simmons,R.L.&Tsung,A.Surgery for Cancer:A Trigger forMetastases.Cancer research 77,1548-1552,doi:10.1158 / 0008-5472.CAN-16-1536(2017).

[0275] Tumeh,P.C.et al.PD-1 blockade induces responses by inhibitingadaptive immune resistance.Nature 515,568-571,doi:10.1038 / nature13954(2014).

[0276] Twyman-Saint Victor,C.et al.Radiation and dual checkpoint blockadeactivate non-redundant immune mechanisms in cancer.Nature 520,373-377,doi:10.1038 / nature14292(2015).

[0277] von Boehmer,H.Mechanisms of suppression by suppressor T cells.Natureimmunology 6,338-344,doi:10.1038 / ni1180(2005).

[0278] W.W.Gibbs,Sci.Am.2005,293,78-83.

[0279] W.Zou,J.D.Wolchok,L.Chen,Sci.Transl.Med.2016,8,328rv324.

[0280] Y.Tian,S.Li,J.Song,T.Ji,M.Zhu,G.J.Anderson,J.Wei,G.Nie,Biomaterials2014,35,2383-2390.

[0281] Y.Ye,J.Wang,Q.Hu,G.M.Hochu,H.Xin,C.Wang,Z.Gu,ACS Nano 2016,10,8956-8963.

[0282] Yoshida,S.,Nomoto,K.,Himeno,K.&Takeya,K.Immune response to syngeneicor autologous testicular cells in mice.I.Augmented delayed footpad reactionin cyclophosphamide-treated mice.Clinical and experimental immunology 38,211-217(1979).

[0283] Zhang,X.et al.The effect of autophagy inhibitors on drug deliveryusing biodegradable polymer nanoparticles in cancer treatment.Biomaterials35,1932-1943,doi:10.1016 / j.biomaterials.2013.10.034(2014).

[0284] Zou,W.Regulatory T cells,tumor immunity and immunotherapy.Nat RevImmunol 6,295-307,doi:10.1038 / nri1806(2006).

[0285] Zou,W.,Wolchok,J.D.&Chen,L.PD-L1(B7-H1)and PD-1 pathway blockade forcancer therapy:Mechanisms,response biomarkers,and combinations.Sciencetranslational medicine 8,328rv324,doi:10.1126 / scitranslmed.aad7118(2016).

Claims

1. An engineered nanovesicle or engineered platelet encoding one or more exogenous protein receptors, wherein the one or more exogenous protein receptors include PD-1, wherein the engineered nanovesicle also encapsulates 1-methyl-tryptophan (1-MT), and the engineered platelet also encapsulates cyclophosphamide.

2. The engineered nanovesicle or engineered platelet according to claim 1, wherein the engineered nanovesicle is derived from stem cells or immune cells.

3. The engineered nanovesicle or engineered platelet according to claim 1, wherein the engineered nanovesicle is derived from a dendritic cell, a megakaryocyte progenitor cell or a macrophage.

4. A pharmaceutical composition comprising the engineered nanovesicle or engineered platelet according to claim 1.

5. The engineered nanovesicle or engineered platelet according to any one of claims 1-3, or the pharmaceutical composition according to claim 4, further comprising an additional therapeutic agent.

6. The engineered nanovesicle or engineered platelet, pharmaceutical composition according to claim 5, wherein the therapeutic agent is encapsulated in the engineered nanovesicle or engineered platelet.

7. The engineered nanovesicle or engineered platelet, pharmaceutical composition according to claim 5, wherein the therapeutic agent is a small molecule.

8. The engineered nanovesicle or engineered platelet, pharmaceutical composition according to claim 5, wherein the therapeutic agent is siRNA, a peptide, a peptidomimetic or an antibody.

9. The engineered nanovesicle or engineered platelet, pharmaceutical composition according to claim 7, wherein the therapeutic agent comprises norharmane, rosmarinic acid, epacadostat, navooximod, doxorubicin, tamoxifen, paclitaxel, vinblastine or 5-fluorouracil.

10. The engineered nanovesicle or engineered platelet, pharmaceutical composition according to claim 8, wherein the therapeutic agent comprises a PD-L1 antibody.

11. The engineered nanovesicle or engineered platelet, or pharmaceutical composition according to claim 10, wherein the antibody is Atexolizumab, Durvalumab, or Avelumab.

12. Use of the engineered nanovesicle or engineered platelet according to any one of claims 1 to 3, or the pharmaceutical composition according to claim 4 in the preparation of a medicament for treating melanoma in a subject.

13. The use of claim 12, wherein the engineered nanovesicles, engineered platelets or pharmaceutical composition is administered at least once every 12 hours, 14 hours, 16 hours, 18 hours, 20 hours, 22 hours, 24 hours, 26 hours, 28 hours, 30 hours, 32 hours, 34 hours, 36 hours, 38 hours, 40 hours, 42 hours, 44 hours, 46 hours, 48 ​​hours, every 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days, 21 days, 22 days, 23 days, 24 days, 25 days, 26 days, 27 days, 28 days, 29 days, 30 days, 31 days, every 2 months, 3 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months, 4 months Administer to patients once every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months.

14. The use according to claim 12, wherein the engineered nanovesicles, engineered platelets or pharmaceutical composition is administered at least 1, 2, 3, 4, 5, 6 or 7 times per week.

15. The use according to claim 12, wherein the dose of the engineered nanovesicle, engineered platelet or pharmaceutical composition administered is 10 mg / kg to 100 mg / kg.

16. The use according to claim 12, further comprising administering a chemotherapeutic agent.

17. The use according to claim 12, wherein the engineered nanovesicles, engineered platelets or pharmaceutical composition is administered after surgical resection of a tumor.

Citation Information

Patent Citations

  • Apparatus for continuously melting of metal

    US3610795A

  • Scraper cleaning apparatus for endless conveyor belt

    US4105109A

  • Cell membrane-derived nanovesicles and use thereof

    US20180036240A1

  • Compositions of platelet-derived theranostics and uses thereof

    WO2016205144A1

  • Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent

    WO2017161032A1